etazolate profile

Etazolate: A potent phosphodiesterase inhibitor proposed as an antipsychotic agent. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

etazolate : A pyrazolopyridine that is 1H-pyrazolo[3,4-b]pyridine which is substituted at positions 1, 4, and 5 by ethyl, 2-isopropylidenehydrazino, and ethoxycarbonyl groups, respectively. A phosphodiesterase IV inhibitor with antidepressant and anxiolytic properties. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	3277
CHEBI ID	138502
CHEBI ID	93135
SCHEMBL ID	123840
MeSH ID	M0007803

Synonym
BRD-K64755930-003-01-6
etazolate
sq-20009
eht-202
eht-0202
HSCI1_000299
NCGC00015403-01
tocris-0438
NCGC00024590-01
lopac-e-1896
nsc163611
etazolate hydrochloride(usan)
sq 20,009
ethyl 1-ethyl-4-(2-isopropylidenehydrazino)pyrazolo[3,4-b]pyridine-5-carboxylate
LOPAC0_000440
etazolato [inn-spanish]
1h-pyrazolo(3,4-b)pyridine-5-carboxylic acid, 1-ethyl-4-((1-methylethylidene)hydrazino)-, ethyl ester
etazolate [inn]
etazolatum [inn-latin]
NCGC00024590-02
ethyl 1-ethyl-4-(2-propan-2-ylidenehydrazinyl)pyrazolo[3,4-b]pyridine-5-carboxylate
CHEBI:138502
ethyl 1-ethyl-4-(2-isopropylidenehydrazino)-1h-pyrazolo[3,4-b]pyridine-5-carboxylate
1-ethyl-4-(2-propan-2-ylidenehydrazinyl)-5-pyrazolo[3,4-b]pyridinecarboxylic acid ethyl ester
etazolatum
ethyl 1-ethyl-4-(2-propan-2-ylidenehydrazinyl)pyrazolo[4,5-e]pyridine-5-carboxylate
sq-20,009
etazolato
ethyl 1-ethyl-4-[2-(1-methylethylidene)hydrazino]-1h-pyrazolo[3,4-b]pyridine-5-carboxylate
HMS2090J08
NCGC00015403-04
51022-77-6
CCG-204532
NCGC00015403-02
NCGC00015403-03
i89y79062l ,
unii-i89y79062l
FT-0625719
ethyl 1-ethyl-4-(isopropylidenehydrazino)-1h-pyrazolo(3,4-b)pyridine-5-carboxylate
1h-pyrazolo[3,4-b]pyridine-5-carboxylicacid, 1-ethyl-4-[2-(1-methylethylidene)hydrazinyl]-, ethyl ester, hydrochloride(1:1)
gtpl7336
SCHEMBL123840
AB01275529-01
DTXSID4048434
OPQRBXUBWHDHPQ-UHFFFAOYSA-N
tox21 111226
CHEBI:93135
1-ethyl-4-(n'-isopropylidene-hydrazino)-1h-pyrazolo[3,4-b]pyridine-5-carboxylic acid ethyl ester
Q5402458
bdbm50225504
BRD-K64755930-003-02-4
SB16896
SDCCGSBI-0050425.P002
3,6-dichloro-5-hydroxy-o-anisicacid
ethyl 1-ethyl-4-(2-(propan-2-ylidene)hydrazineyl)-1h-pyrazolo[3,4-b]pyridine-5-carboxylate
ethyl 1-ethyl-4-[2-(propan-2-ylidene)hydrazin-1-yl]-1h-pyrazolo[3,4-b]pyridine-5-carboxylate

Excerpt	Reference
"Etazolate is a selective phosphodiesterase-4 inhibitor that is specific for cAMP."	( Al Subeh, ZY; Alzoubi, KH; Khabour, OF, 2017)
"Etazolate is a selective phosphodiesterase IV inhibitor that is highly specific for cAMP, which has anxiolytic and antidepressant effects."	( Al Subeh, ZY; Alzoubi, KH; Khabour, OF, 2019)
"Etazolate is a selective inhibitor of type 4 phosphodiesterase (PDE4) class enzyme. "	( Ankur, J; Bhatt, S; Mahesh, R, 2013)
"Etazolate (ETZ) is a new generation PDE4 inhibitor with encouraging safety and tolerance profiles."	( Bhatt, S; Jindal, A; Mahesh, R; Pandey, D, 2017)
"Etazolate is a phosphodiesterase 4 (PDE4) inhibitor and GABAA receptor modulator that also stimulates alpha-secretase activity and neurotrophic soluble amyloid precursor protein (sAPPalpha) production, currently developed as a possible Alzheimer's disease therapeutic. "	( Desire, L; Drott, J; Drouin, D; Haun, F; Pando, M, 2010)

Excerpt	Reference
"Etazolate does not increase glycine-mediated conductance changes."	( Barnes, DM; Dichter, MA; White, WF, 1983)

Excerpt	Reference
"Etazolate treatment was able to i) enhance the release of sAPPα in the culture media of demyelinated slices, ii) protect myelinated axons from demyelination, iii) increase the number of mature oligodendrocytes, iv) promote the reappearance of the paired Caspr"	( Allinquant, B; Camand, E; Carrete, A; Chierto, E; Hendriks, JJA; Jafarian-Tehrani, M; Llufriu-Dabén, G; Mailleux, J; Massaad, C; Meffre, D; Rose, C; Simon, A; Vanmierlo, T, 2018)
"Etazolate treatment, on the other hand, led to prevention of changes in these oxidative stress biomarkers (GSH, GSSG, GPx and TBARS), BDNF levels, and histones acetylation."	( Al Subeh, ZY; Alzoubi, KH; Khabour, OF, 2019)

Role	Description
neuroprotective agent	Any compound that can be used for the treatment of neurodegenerative disorders.
antipsychotic agent	Antipsychotic drugs are agents that control agitated psychotic behaviour, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect.
phosphodiesterase IV inhibitor	An EC 3.1.4.53 (3',5'-cyclic-AMP phosphodiesterase) inhibitor that specifically blocks the action of phosphodiesterase IV.
anxiolytic drug	Anxiolytic drugs are agents that alleviate anxiety, tension, and anxiety disorders, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions.
antidepressant	Antidepressants are mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions.
alpha-secretase activator	An activator of alpha-secretase, one of the three endopeptidases that are specific for amyloid protein precursor and which have been identified based upon the region of the amyloid protein precursor which they cleave.
GABA agent	A substance, such as agonists, antagonists, degradation or uptake inhibitors, depleters, precursors, and modulators of receptor function, used for its pharmacological actions on GABAergic systems.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
pyrazolopyridine
hydrazone	Compounds having the structure R2C=NNR2, formally derived from aldehydes or ketones by replacing =O by =NNH2 (or substituted analogues).
ethyl ester	Any carboxylic ester resulting from the formal condensation of the carboxy group of a carboxylic acid with ethanol.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, HADH2 protein	Homo sapiens (human)	Potency	27.8675	0.0251	20.2376	39.8107	AID886; AID893
Chain B, HADH2 protein	Homo sapiens (human)	Potency	27.8675	0.0251	20.2376	39.8107	AID886; AID893
Chain A, 2-oxoglutarate Oxygenase	Homo sapiens (human)	Potency	35.4813	0.1778	14.3909	39.8107	AID2147
Chain A, Cruzipain	Trypanosoma cruzi	Potency	39.8107	0.0020	14.6779	39.8107	AID1476
thioredoxin reductase	Rattus norvegicus (Norway rat)	Potency	16.0014	0.1000	20.8793	79.4328	AID588453; AID588456
GLS protein	Homo sapiens (human)	Potency	10.0000	0.3548	7.9355	39.8107	AID624146
TDP1 protein	Homo sapiens (human)	Potency	26.6086	0.0008	11.3822	44.6684	AID686978
arylsulfatase A	Homo sapiens (human)	Potency	4.2562	1.0691	13.9551	37.9330	AID720538
euchromatic histone-lysine N-methyltransferase 2	Homo sapiens (human)	Potency	29.9349	0.0355	20.9770	89.1251	AID504332
cytochrome P450 2C19 precursor	Homo sapiens (human)	Potency	10.0000	0.0025	5.8400	31.6228	AID899
cytochrome P450 2C9 precursor	Homo sapiens (human)	Potency	31.6228	0.0063	6.9043	39.8107	AID883
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1	Homo sapiens (human)	Potency	28.1838	0.0018	15.6638	39.8107	AID894
mitogen-activated protein kinase 1	Homo sapiens (human)	Potency	18.8541	0.0398	16.7842	39.8107	AID995
cytochrome P450 3A4 isoform 1	Homo sapiens (human)	Potency	14.2191	0.0316	10.2792	39.8107	AID884; AID885
muscarinic acetylcholine receptor M1	Rattus norvegicus (Norway rat)	Potency	7.9433	0.0010	6.0009	35.4813	AID944
Gamma-aminobutyric acid receptor subunit pi	Rattus norvegicus (Norway rat)	Potency	14.2191	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit beta-1	Rattus norvegicus (Norway rat)	Potency	14.2191	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit delta	Rattus norvegicus (Norway rat)	Potency	14.2191	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit gamma-2	Rattus norvegicus (Norway rat)	Potency	14.2191	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-5	Rattus norvegicus (Norway rat)	Potency	14.2191	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-3	Rattus norvegicus (Norway rat)	Potency	14.2191	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit gamma-1	Rattus norvegicus (Norway rat)	Potency	14.2191	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-2	Rattus norvegicus (Norway rat)	Potency	14.2191	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-4	Rattus norvegicus (Norway rat)	Potency	14.2191	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit gamma-3	Rattus norvegicus (Norway rat)	Potency	14.2191	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-6	Rattus norvegicus (Norway rat)	Potency	14.2191	1.0000	12.2248	31.6228	AID885
Histamine H2 receptor	Cavia porcellus (domestic guinea pig)	Potency	31.6228	0.0063	8.2350	39.8107	AID883
Gamma-aminobutyric acid receptor subunit alpha-1	Rattus norvegicus (Norway rat)	Potency	14.2191	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit beta-3	Rattus norvegicus (Norway rat)	Potency	14.2191	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit beta-2	Rattus norvegicus (Norway rat)	Potency	14.2191	1.0000	12.2248	31.6228	AID885
GABA theta subunit	Rattus norvegicus (Norway rat)	Potency	14.2191	1.0000	12.2248	31.6228	AID885
CREB-binding protein	Homo sapiens (human)	Potency	5.4415	0.0282	2.3600	12.5893	AID906; AID907; AID916
Gamma-aminobutyric acid receptor subunit epsilon	Rattus norvegicus (Norway rat)	Potency	14.2191	1.0000	12.2248	31.6228	AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A	Homo sapiens (human)	Ki	60.0000	9.5000	9.7500	10.0000	AID158908
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B	Homo sapiens (human)	Ki	60.0000	9.5000	9.7500	10.0000	AID158908
cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)	IC50 (µMol)	0.3900	0.0000	1.1463	10.0000	AID1720010
cGMP-inhibited 3',5'-cyclic phosphodiesterase B	Homo sapiens (human)	Ki	12.0000	0.0050	0.3381	1.4000	AID158444
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1C	Homo sapiens (human)	Ki	60.0000	9.5000	9.7500	10.0000	AID158908
cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)	Ki	12.0000	0.0050	0.3209	1.4000	AID158444
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
regulation of smooth muscle cell apoptotic process	Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A	Homo sapiens (human)
cGMP catabolic process	Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A	Homo sapiens (human)
regulation of smooth muscle cell proliferation	Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A	Homo sapiens (human)
cAMP-mediated signaling	Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A	Homo sapiens (human)
response to amphetamine	Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B	Homo sapiens (human)
locomotory behavior	Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B	Homo sapiens (human)
visual learning	Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B	Homo sapiens (human)
monocyte differentiation	Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B	Homo sapiens (human)
cellular response to macrophage colony-stimulating factor stimulus	Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B	Homo sapiens (human)
dopamine catabolic process	Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B	Homo sapiens (human)
serotonin metabolic process	Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B	Homo sapiens (human)
cellular response to granulocyte macrophage colony-stimulating factor stimulus	Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B	Homo sapiens (human)
cAMP-mediated signaling	Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B	Homo sapiens (human)
regulation of heart rate	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
cAMP catabolic process	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
positive regulation of heart rate	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulum	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
positive regulation of type II interferon production	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
positive regulation of interleukin-2 production	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
positive regulation of interleukin-5 production	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
negative regulation of peptidyl-serine phosphorylation	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
negative regulation of heart contraction	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
T cell receptor signaling pathway	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
establishment of endothelial barrier	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
adrenergic receptor signaling pathway	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
regulation of cardiac muscle cell contraction	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
negative regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathway	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
regulation of cell communication by electrical coupling involved in cardiac conduction	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
negative regulation of relaxation of cardiac muscle	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
regulation of calcium ion transmembrane transport via high voltage-gated calcium channel	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
cAMP-mediated signaling	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
angiogenesis	cGMP-inhibited 3',5'-cyclic phosphodiesterase B	Homo sapiens (human)
negative regulation of cell adhesion	cGMP-inhibited 3',5'-cyclic phosphodiesterase B	Homo sapiens (human)
G protein-coupled receptor signaling pathway	cGMP-inhibited 3',5'-cyclic phosphodiesterase B	Homo sapiens (human)
negative regulation of angiogenesis	cGMP-inhibited 3',5'-cyclic phosphodiesterase B	Homo sapiens (human)
cellular response to insulin stimulus	cGMP-inhibited 3',5'-cyclic phosphodiesterase B	Homo sapiens (human)
negative regulation of cell adhesion mediated by integrin	cGMP-inhibited 3',5'-cyclic phosphodiesterase B	Homo sapiens (human)
negative regulation of lipid catabolic process	cGMP-inhibited 3',5'-cyclic phosphodiesterase B	Homo sapiens (human)
negative regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathway	cGMP-inhibited 3',5'-cyclic phosphodiesterase B	Homo sapiens (human)
cAMP-mediated signaling	cGMP-inhibited 3',5'-cyclic phosphodiesterase B	Homo sapiens (human)
cAMP-mediated signaling	Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1C	Homo sapiens (human)
oocyte maturation	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)
lipid metabolic process	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)
G protein-coupled receptor signaling pathway	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)
response to xenobiotic stimulus	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)
cAMP-mediated signaling	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)
cGMP-mediated signaling	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)
regulation of meiotic nuclear division	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)
negative regulation of apoptotic process	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)
negative regulation of vascular permeability	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)
positive regulation of vascular permeability	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)
steroid hormone mediated signaling pathway	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)
negative regulation of cAMP-mediated signaling	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)
positive regulation of oocyte development	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)
regulation of ribonuclease activity	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)
cellular response to cGMP	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)
cellular response to transforming growth factor beta stimulus	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)
apoptotic signaling pathway	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)
negative regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathway	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	CREB-binding protein	Homo sapiens (human)
response to hypoxia	CREB-binding protein	Homo sapiens (human)
stimulatory C-type lectin receptor signaling pathway	CREB-binding protein	Homo sapiens (human)
chromatin remodeling	CREB-binding protein	Homo sapiens (human)
regulation of DNA-templated transcription	CREB-binding protein	Homo sapiens (human)
protein acetylation	CREB-binding protein	Homo sapiens (human)
signal transduction	CREB-binding protein	Homo sapiens (human)
canonical NF-kappaB signal transduction	CREB-binding protein	Homo sapiens (human)
regulation of smoothened signaling pathway	CREB-binding protein	Homo sapiens (human)
negative regulation of transcription by RNA polymerase I	CREB-binding protein	Homo sapiens (human)
N-terminal peptidyl-lysine acetylation	CREB-binding protein	Homo sapiens (human)
positive regulation of transforming growth factor beta receptor signaling pathway	CREB-binding protein	Homo sapiens (human)
protein destabilization	CREB-binding protein	Homo sapiens (human)
cellular response to nutrient levels	CREB-binding protein	Homo sapiens (human)
cellular response to UV	CREB-binding protein	Homo sapiens (human)
homeostatic process	CREB-binding protein	Homo sapiens (human)
embryonic digit morphogenesis	CREB-binding protein	Homo sapiens (human)
positive regulation of DNA-templated transcription	CREB-binding protein	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	CREB-binding protein	Homo sapiens (human)
rhythmic process	CREB-binding protein	Homo sapiens (human)
protein-containing complex assembly	CREB-binding protein	Homo sapiens (human)
regulation of cellular response to heat	CREB-binding protein	Homo sapiens (human)
positive regulation of protein localization to nucleus	CREB-binding protein	Homo sapiens (human)
positive regulation of double-strand break repair via homologous recombination	CREB-binding protein	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
calmodulin-activated dual specificity 3',5'-cyclic-GMP, 3',5'-cyclic-AMP phosphodiesterase activity	Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A	Homo sapiens (human)
calmodulin binding	Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A	Homo sapiens (human)
metal ion binding	Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A	Homo sapiens (human)
calmodulin-activated 3',5'-cyclic-GMP phosphodiesterase activity	Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A	Homo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activity	Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B	Homo sapiens (human)
calmodulin-activated dual specificity 3',5'-cyclic-GMP, 3',5'-cyclic-AMP phosphodiesterase activity	Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B	Homo sapiens (human)
protein binding	Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B	Homo sapiens (human)
calmodulin binding	Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B	Homo sapiens (human)
metal ion binding	Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B	Homo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activity	Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B	Homo sapiens (human)
calmodulin-activated 3',5'-cyclic-GMP phosphodiesterase activity	Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B	Homo sapiens (human)
3',5'-cyclic-nucleotide phosphodiesterase activity	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activity	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
calcium channel regulator activity	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
protein binding	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
enzyme binding	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
signaling receptor regulator activity	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
cAMP binding	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
beta-2 adrenergic receptor binding	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
transmembrane transporter binding	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
metal ion binding	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
ATPase binding	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
scaffold protein binding	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
heterocyclic compound binding	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activity	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
3',5'-cyclic-nucleotide phosphodiesterase activity	cGMP-inhibited 3',5'-cyclic phosphodiesterase B	Homo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activity	cGMP-inhibited 3',5'-cyclic phosphodiesterase B	Homo sapiens (human)
cGMP-inhibited cyclic-nucleotide phosphodiesterase activity	cGMP-inhibited 3',5'-cyclic phosphodiesterase B	Homo sapiens (human)
protein binding	cGMP-inhibited 3',5'-cyclic phosphodiesterase B	Homo sapiens (human)
protein kinase B binding	cGMP-inhibited 3',5'-cyclic phosphodiesterase B	Homo sapiens (human)
metal ion binding	cGMP-inhibited 3',5'-cyclic phosphodiesterase B	Homo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activity	cGMP-inhibited 3',5'-cyclic phosphodiesterase B	Homo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activity	Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1C	Homo sapiens (human)
calmodulin-activated dual specificity 3',5'-cyclic-GMP, 3',5'-cyclic-AMP phosphodiesterase activity	Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1C	Homo sapiens (human)
calmodulin binding	Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1C	Homo sapiens (human)
metal ion binding	Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1C	Homo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activity	Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1C	Homo sapiens (human)
calmodulin-activated 3',5'-cyclic-GMP phosphodiesterase activity	Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1C	Homo sapiens (human)
3',5'-cyclic-nucleotide phosphodiesterase activity	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activity	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)
cGMP-inhibited cyclic-nucleotide phosphodiesterase activity	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)
protein binding	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)
nuclear estrogen receptor activity	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)
metal ion binding	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activity	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)
estrogen binding	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)
transcription coactivator binding	CREB-binding protein	Homo sapiens (human)
p53 binding	CREB-binding protein	Homo sapiens (human)
chromatin binding	CREB-binding protein	Homo sapiens (human)
damaged DNA binding	CREB-binding protein	Homo sapiens (human)
transcription coactivator activity	CREB-binding protein	Homo sapiens (human)
transcription corepressor activity	CREB-binding protein	Homo sapiens (human)
histone acetyltransferase activity	CREB-binding protein	Homo sapiens (human)
protein binding	CREB-binding protein	Homo sapiens (human)
zinc ion binding	CREB-binding protein	Homo sapiens (human)
acetyltransferase activity	CREB-binding protein	Homo sapiens (human)
peptide N-acetyltransferase activity	CREB-binding protein	Homo sapiens (human)
MRF binding	CREB-binding protein	Homo sapiens (human)
histone H3K18 acetyltransferase activity	CREB-binding protein	Homo sapiens (human)
histone H3K27 acetyltransferase activity	CREB-binding protein	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	CREB-binding protein	Homo sapiens (human)
peptide-lysine-N-acetyltransferase activity	CREB-binding protein	Homo sapiens (human)
peptide lactyltransferase activity	CREB-binding protein	Homo sapiens (human)
DNA-binding transcription factor binding	CREB-binding protein	Homo sapiens (human)
chromatin DNA binding	CREB-binding protein	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	Gamma-aminobutyric acid receptor subunit gamma-2	Rattus norvegicus (Norway rat)
cytosol	Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A	Homo sapiens (human)
neuronal cell body	Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A	Homo sapiens (human)
plasma membrane	Gamma-aminobutyric acid receptor subunit alpha-1	Rattus norvegicus (Norway rat)
plasma membrane	Gamma-aminobutyric acid receptor subunit beta-2	Rattus norvegicus (Norway rat)
cytosol	Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B	Homo sapiens (human)
neuronal cell body	Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B	Homo sapiens (human)
centrosome	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
cytosol	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
plasma membrane	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
apical plasma membrane	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
voltage-gated calcium channel complex	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
calcium channel complex	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
cytosol	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
nucleus	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
perinuclear region of cytoplasm	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
endoplasmic reticulum	cGMP-inhibited 3',5'-cyclic phosphodiesterase B	Homo sapiens (human)
Golgi apparatus	cGMP-inhibited 3',5'-cyclic phosphodiesterase B	Homo sapiens (human)
cytosol	cGMP-inhibited 3',5'-cyclic phosphodiesterase B	Homo sapiens (human)
membrane	cGMP-inhibited 3',5'-cyclic phosphodiesterase B	Homo sapiens (human)
guanyl-nucleotide exchange factor complex	cGMP-inhibited 3',5'-cyclic phosphodiesterase B	Homo sapiens (human)
lysosome	Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1C	Homo sapiens (human)
cytosol	Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1C	Homo sapiens (human)
neuronal cell body	Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1C	Homo sapiens (human)
cytosol	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)
membrane	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)
cytosol	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)
cytoplasm	CREB-binding protein	Homo sapiens (human)
nucleus	CREB-binding protein	Homo sapiens (human)
nucleoplasm	CREB-binding protein	Homo sapiens (human)
cytoplasm	CREB-binding protein	Homo sapiens (human)
cytosol	CREB-binding protein	Homo sapiens (human)
nuclear body	CREB-binding protein	Homo sapiens (human)
chromatin	CREB-binding protein	Homo sapiens (human)
histone acetyltransferase complex	CREB-binding protein	Homo sapiens (human)
transcription regulator complex	CREB-binding protein	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (38)

Assay ID	Title	Year	Journal	Article
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504836	Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation	2002	The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16	Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1508627	Counterscreen qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: GLuc-NoTag assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347049	Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347410	qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library	2019	Cellular signalling, 08, Volume: 60	A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347152	Confirmatory screen NINDS AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID588378	qHTS for Inhibitors of ATXN expression: Validation
AID588349	qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347059	CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347050	Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347168	HepG2 cells viability qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347151	Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347161	Confirmatory screen NINDS Rhodamine qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508629	Cell Viability qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347057	CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347405	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347153	Confirmatory screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347149	Furin counterscreen qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347169	Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347045	Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347058	CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347167	Vero cells viability qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508628	Confirmatory qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID205269	Inhibition of binding of Batrachotoxinin [3H]BTX-B to high-affinity sites on voltage-dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex at 100 uM	1985	Journal of medicinal chemistry, Mar, Volume: 28, Issue:3	[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.
AID205268	Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex at 10 uM	1985	Journal of medicinal chemistry, Mar, Volume: 28, Issue:3	[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.
AID1380118	Inhibition of PDE4 (unknown origin)	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Novel Phosphodiesterase Inhibitors for Cognitive Improvement in Alzheimer's Disease.
AID1720010	Inhibition of PDE4D3 (unknown origin)	2020	Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19	Advances in the Development of Phosphodiesterase-4 Inhibitors.
AID468443	Inhibition of human FAAH at 1 uM	2009	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23	Mining biologically-active molecules for inhibitors of fatty acid amide hydrolase (FAAH): identification of phenmedipham and amperozide as FAAH inhibitors.
AID158908	Binding affinity for [Ca(2+)]/calmodulin dependent phosphodiesterase PDE 1 of sheep lung	1985	Journal of medicinal chemistry, May, Volume: 28, Issue:5	A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity.
AID158444	Binding affinity for low Km cAMP phosphodiesterase PDE III of sheep lung	1985	Journal of medicinal chemistry, May, Volume: 28, Issue:5	A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity.
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1346515	Human GABAA receptor beta3 subunit (GABAA receptors)	1996	European journal of pharmacology, Apr-22, Volume: 301, Issue:1-3	Interaction of allosteric ligands with GABAA receptors containing one, two, or three different subunits.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	53 (59.55)	18.7374
1990's	3 (3.37)	18.2507
2000's	5 (5.62)	29.6817
2010's	21 (23.60)	24.3611
2020's	7 (7.87)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	1 (1.09%)	5.53%
Reviews	9 (9.78%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	82 (89.13%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Pilot, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicentre, Phase IIA Study to Determine the Clinical Safety/Tolerability and Exploratory Efficacy of EHT 0202 (40 and 80 mg Bid) as Adjunctive Therapy to Acetylcholinesterase Inhibit[NCT00880412]	Phase 2	197 participants (Actual)	Interventional	2008-04-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Substance	Description	Relationhip Strength	Studies	Classes	Roles
quinacrine	[no description available]	medium	1	acridines; aromatic ether; organochlorine compound; tertiary amino compound	antimalarial; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor
gallopamil	[no description available]	medium	1	benzenes; organic amino compound
4-aminopyridine	[no description available]	medium	1	aminopyridine; aromatic amine	avicide; orphan drug; potassium channel blocker
phenytoin	[no description available]	medium	2	imidazolidine-2,4-dione	anticonvulsant; drug allergen; sodium channel blocker; teratogenic agent
8-(4-sulfophenyl)theophylline	[no description available]	medium	1
8-phenyltheophylline	[no description available]	medium	1
theophylline	[no description available]	medium	14	dimethylxanthine	adenosine receptor antagonist; anti-asthmatic drug; anti-inflammatory agent; bronchodilator agent; drug metabolite; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; fungal metabolite; human blood serum metabolite; immunomodulator; muscle relaxant; vasodilator agent
amitriptyline	[no description available]	medium	1	carbotricyclic compound; tertiary amine	adrenergic uptake inhibitor; antidepressant; environmental contaminant; tropomyosin-related kinase B receptor agonist; xenobiotic
anisindione	[no description available]	medium	1	aromatic ketone; beta-diketone	anticoagulant; vitamin K antagonist
baclofen	[no description available]	medium	1	amino acid zwitterion; gamma-amino acid; monocarboxylic acid; monochlorobenzenes; primary amino compound	central nervous system depressant; GABA agonist; muscle relaxant
benzocaine	[no description available]	medium	1	benzoate ester; substituted aniline	allergen; antipruritic drug; sensitiser; topical anaesthetic
bepridil	[no description available]	medium	1	pyrrolidines; tertiary amine	anti-arrhythmia drug; antihypertensive agent; calcium channel blocker; vasodilator agent
biperiden	[no description available]	medium	1	piperidines; tertiary alcohol; tertiary amino compound	antidote to sarin poisoning; antidyskinesia agent; antiparkinson drug; muscarinic antagonist; parasympatholytic
bupivacaine	[no description available]	medium	1	aromatic amide; piperidinecarboxamide; tertiary amino compound
buspirone	[no description available]	medium	2	azaspiro compound; N-alkylpiperazine; N-arylpiperazine; organic heteropolycyclic compound; piperidones; pyrimidines	anxiolytic drug; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; sedative; serotonergic agonist
butacaine	[no description available]	medium	1	benzoate ester
butamben	[no description available]	medium	1	amino acid ester; benzoate ester; primary amino compound; substituted aniline	local anaesthetic
caffeine	[no description available]	medium	7	purine alkaloid; trimethylxanthine	adenosine A2A receptor antagonist; adenosine receptor antagonist; adjuvant; central nervous system stimulant; diuretic; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; environmental contaminant; food additive; fungal metabolite; geroprotector; human blood serum metabolite; mouse metabolite; mutagen; plant metabolite; psychotropic drug; ryanodine receptor agonist; xenobiotic
verapamil	[no description available]	medium	1	aromatic ether; nitrile; polyether; tertiary amino compound
carbamazepine	[no description available]	medium	1	dibenzoazepine; ureas	analgesic; anticonvulsant; antimanic drug; drug allergen; EC 3.5.1.98 (histone deacetylase) inhibitor; environmental contaminant; glutamate transporter activator; mitogen; non-narcotic analgesic; sodium channel blocker; xenobiotic
chlordiazepoxide	[no description available]	medium	1	benzodiazepine
chlorpheniramine	[no description available]	medium	1	monochlorobenzenes; pyridines; tertiary amino compound	anti-allergic agent; antidepressant; antipruritic drug; H1-receptor antagonist; histamine antagonist; serotonin uptake inhibitor
chlorpromazine	[no description available]	medium	1	organochlorine compound; phenothiazines; tertiary amine	anticoronaviral agent; antiemetic; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; phenothiazine antipsychotic drug
cimetidine	[no description available]	medium	1	aliphatic sulfide; guanidines; imidazoles; nitrile	adjuvant; analgesic; anti-ulcer drug; H2-receptor antagonist; P450 inhibitor
clomipramine	[no description available]	medium	1	dibenzoazepine	anticoronaviral agent; antidepressant; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; serotonergic antagonist; serotonergic drug; serotonin uptake inhibitor
cyproheptadine	[no description available]	medium	1	piperidines; tertiary amine	anti-allergic agent; antipruritic drug; gastrointestinal drug; H1-receptor antagonist; serotonergic antagonist
desipramine	[no description available]	medium	1	dibenzoazepine; secondary amino compound	adrenergic uptake inhibitor; alpha-adrenergic antagonist; antidepressant; cholinergic antagonist; drug allergen; EC 3.1.4.12 (sphingomyelin phosphodiesterase) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; H1-receptor antagonist; serotonin uptake inhibitor
diazepam	[no description available]	high	4	1,4-benzodiazepinone; organochlorine compound	anticonvulsant; anxiolytic drug; environmental contaminant; sedative; xenobiotic
diazoxide	[no description available]	medium	1	benzothiadiazine; organochlorine compound; sulfone	antihypertensive agent; beta-adrenergic agonist; bronchodilator agent; cardiotonic drug; diuretic; K-ATP channel agonist; sodium channel blocker; sympathomimetic agent; vasodilator agent
dibucaine	[no description available]	medium	1	aromatic ether; monocarboxylic acid amide; tertiary amino compound	topical anaesthetic
dicyclomine	[no description available]	medium	1	carboxylic ester; tertiary amine	antispasmodic drug; muscarinic antagonist; parasympatholytic
diphenidol	[no description available]	medium	1	benzenes; piperidines; tertiary alcohol	antiemetic
dilazep	[no description available]	medium	1	benzoate ester; diazepane; diester; methoxybenzenes	cardioprotective agent; platelet aggregation inhibitor; vasodilator agent
diphenhydramine	[no description available]	medium	1	ether; tertiary amino compound	anti-allergic agent; antidyskinesia agent; antiemetic; antiparkinson drug; antipruritic drug; antitussive; H1-receptor antagonist; local anaesthetic; muscarinic antagonist; oneirogen; sedative
dipyridamole	[no description available]	medium	3	piperidines; pyrimidopyrimidine; tertiary amino compound; tetrol	adenosine phosphodiesterase inhibitor; EC 3.5.4.4 (adenosine deaminase) inhibitor; platelet aggregation inhibitor; vasodilator agent
doxepin	[no description available]	medium	1	dibenzooxepine; tertiary amino compound	antidepressant
droperidol	[no description available]	medium	2	aromatic ketone; benzimidazoles; organofluorine compound	anaesthesia adjuvant; antiemetic; dopaminergic antagonist; first generation antipsychotic
felodipine	[no description available]	medium	1	dichlorobenzene; dihydropyridine; ethyl ester; methyl ester	anti-arrhythmia drug; antihypertensive agent; calcium channel blocker; vasodilator agent
flufenamic acid	[no description available]	medium	1	aromatic amino acid; organofluorine compound	antipyretic; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
fluphenazine	[no description available]	medium	1	N-alkylpiperazine; organofluorine compound; phenothiazines	anticoronaviral agent; dopaminergic antagonist; phenothiazine antipsychotic drug
flumazenil	[no description available]	high	2	ethyl ester; imidazobenzodiazepine; organofluorine compound	antidote to benzodiazepine poisoning; GABA antagonist
haloperidol	[no description available]	medium	1	aromatic ketone; hydroxypiperidine; monochlorobenzenes; organofluorine compound; tertiary alcohol	antidyskinesia agent; antiemetic; dopaminergic antagonist; first generation antipsychotic; serotonergic antagonist
hydroxyzine	[no description available]	medium	1	hydroxyether; monochlorobenzenes; N-alkylpiperazine	anticoronaviral agent; antipruritic drug; anxiolytic drug; dermatologic drug; H1-receptor antagonist
lidocaine	[no description available]	medium	1	benzenes; monocarboxylic acid amide; tertiary amino compound	anti-arrhythmia drug; drug allergen; environmental contaminant; local anaesthetic; xenobiotic
ici 118551	[no description available]	medium	1	indanes
imipramine	[no description available]	medium	1	dibenzoazepine	adrenergic uptake inhibitor; antidepressant; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
indomethacin	[no description available]	medium	2	aromatic ether; indole-3-acetic acids; monochlorobenzenes; N-acylindole	analgesic; drug metabolite; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; gout suppressant; non-steroidal anti-inflammatory drug; xenobiotic metabolite; xenobiotic
1-methyl-3-isobutylxanthine	[no description available]	medium	7	3-isobutyl-1-methylxanthine
loperamide	[no description available]	medium	1	monocarboxylic acid amide; monochlorobenzenes; piperidines; tertiary alcohol	anticoronaviral agent; antidiarrhoeal drug; mu-opioid receptor agonist
mepivacaine	[no description available]	medium	1	piperidinecarboxamide	drug allergen; local anaesthetic
benzoic acid [2-methyl-2-(propylamino)propyl] ester	[no description available]	medium	1	benzoate ester
metoprolol	[no description available]	medium	1	aromatic ether; propanolamine; secondary alcohol; secondary amino compound	antihypertensive agent; beta-adrenergic antagonist; environmental contaminant; geroprotector; xenobiotic
mianserin	[no description available]	medium	1	dibenzoazepine	adrenergic uptake inhibitor; alpha-adrenergic antagonist; antidepressant; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; geroprotector; H1-receptor antagonist; histamine agonist; sedative; serotonergic antagonist
nifedipine	[no description available]	medium	1	C-nitro compound; dihydropyridine; methyl ester	calcium channel blocker; human metabolite; tocolytic agent; vasodilator agent
nisoldipine	[no description available]	medium	1	C-nitro compound; dicarboxylic acids and O-substituted derivatives; diester; dihydropyridine; methyl ester
nitrendipine	[no description available]	medium	1	C-nitro compound; dicarboxylic acids and O-substituted derivatives; diester; dihydropyridine; ethyl ester; methyl ester	antihypertensive agent; calcium channel blocker; geroprotector; vasodilator agent
nortriptyline	[no description available]	medium	1	organic tricyclic compound; secondary amine	adrenergic uptake inhibitor; analgesic; antidepressant; antineoplastic agent; apoptosis inducer; drug metabolite
oxethazaine	[no description available]	medium	1	amino acid amide
benoxinate	[no description available]	medium	1	amino acid ester; benzoate ester; substituted aniline; tertiary amino compound	drug allergen; local anaesthetic; topical anaesthetic
papaverine	[no description available]	medium	6	benzylisoquinoline alkaloid; dimethoxybenzene; isoquinolines	antispasmodic drug; vasodilator agent
pentobarbital	[no description available]	medium	5	barbiturates	GABAA receptor agonist
pheniramine	[no description available]	medium	1	pyridines; tertiary amino compound
phenobarbital	[no description available]	medium	2	barbiturates	anticonvulsant; drug allergen; excitatory amino acid antagonist; sedative
phenoxybenzamine	[no description available]	medium	1	aromatic amine
practolol	[no description available]	medium	1	acetamides; ethanolamines; propanolamine; secondary alcohol; secondary amino compound	anti-arrhythmia drug; beta-adrenergic antagonist
pramoxine	[no description available]	medium	1	aromatic ether; morpholines	local anaesthetic
prazosin	[no description available]	medium	1	aromatic ether; furans; monocarboxylic acid amide; piperazines; quinazolines	alpha-adrenergic antagonist; antihypertensive agent; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
prilocaine	[no description available]	medium	1	amino acid amide; monocarboxylic acid amide	anticonvulsant; local anaesthetic
proadifen	[no description available]	medium	1	diarylmethane
procainamide	[no description available]	medium	1	benzamides	anti-arrhythmia drug; platelet aggregation inhibitor; sodium channel blocker
procaine	[no description available]	medium	1	benzoate ester; substituted aniline; tertiary amino compound	central nervous system depressant; drug allergen; local anaesthetic; peripheral nervous system drug
promazine	[no description available]	medium	1	phenothiazines; tertiary amine	antiemetic; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; H1-receptor antagonist; muscarinic antagonist; phenothiazine antipsychotic drug; serotonergic antagonist
promethazine	[no description available]	medium	1	phenothiazines; tertiary amine	anti-allergic agent; anticoronaviral agent; antiemetic; antipruritic drug; H1-receptor antagonist; local anaesthetic; sedative
proxymetacaine	[no description available]	medium	1	benzoate ester
protriptyline	[no description available]	medium	1	carbotricyclic compound	antidepressant
pyrilamine	[no description available]	medium	1	aromatic ether; ethylenediamine derivative	H1-receptor antagonist
4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone	[no description available]	medium	8	methoxybenzenes
rolipram	[no description available]	high	5	pyrrolidin-2-ones	antidepressant; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor
secobarbital	[no description available]	medium	1	barbiturates	anaesthesia adjuvant; GABA modulator; sedative
sotalol	[no description available]	medium	2	ethanolamines; secondary alcohol; secondary amino compound; sulfonamide	anti-arrhythmia drug; beta-adrenergic antagonist; environmental contaminant; xenobiotic
spiperone	[no description available]	medium	1	aromatic ketone; azaspiro compound; organofluorine compound; piperidines; tertiary amino compound	alpha-adrenergic antagonist; antipsychotic agent; dopaminergic antagonist; psychotropic drug; serotonergic antagonist
tetracaine	[no description available]	medium	1	benzoate ester; tertiary amino compound	local anaesthetic
thioridazine	[no description available]	medium	1	phenothiazines; piperidines	alpha-adrenergic antagonist; dopaminergic antagonist; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; first generation antipsychotic; H1-receptor antagonist; serotonergic antagonist
trazodone	[no description available]	medium	2	monochlorobenzenes; N-alkylpiperazine; N-arylpiperazine; triazolopyridine	adrenergic antagonist; antidepressant; anxiolytic drug; H1-receptor antagonist; sedative; serotonin uptake inhibitor
trequinsin	[no description available]	medium	1	pyridopyrimidine
trifluoperazine	[no description available]	medium	1	N-alkylpiperazine; N-methylpiperazine; organofluorine compound; phenothiazines	antiemetic; calmodulin antagonist; dopaminergic antagonist; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; EC 5.3.3.5 (cholestenol Delta-isomerase) inhibitor; phenothiazine antipsychotic drug
reserpine	[no description available]	medium	1	alkaloid ester; methyl ester; yohimban alkaloid	adrenergic uptake inhibitor; antihypertensive agent; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; environmental contaminant; first generation antipsychotic; plant metabolite; xenobiotic
phentolamine	[no description available]	medium	2	imidazoles; phenols; substituted aniline; tertiary amino compound	alpha-adrenergic antagonist; vasodilator agent
hexobendine	[no description available]	medium	1	trihydroxybenzoic acid
dichloroisoproterenol	[no description available]	medium	1
tetraethylammonium chloride	[no description available]	medium	1	organic chloride salt; quaternary ammonium salt	potassium channel blocker
tetrabenazine	[no description available]	medium	1	benzoquinolizine; cyclic ketone; tertiary amino compound
piperoxan	[no description available]	medium	1
nifenalol	[no description available]	medium	1	C-nitro compound
brompheniramine	[no description available]	medium	1	organobromine compound; pyridines	anti-allergic agent; H1-receptor antagonist
propoxycaine	[no description available]	medium	1	benzoate ester
dimethisoquin	[no description available]	medium	1	isoquinolines
parethoxycaine	[no description available]	medium	1	benzoate ester
yohimbine	[no description available]	medium	1	methyl 17-hydroxy-20xi-yohimban-16-carboxylate	alpha-adrenergic antagonist; dopamine receptor D2 antagonist; serotonergic antagonist
2-chloroadenosine	[no description available]	medium	1	purine nucleoside
prenylamine	[no description available]	medium	1	diarylmethane
bicuculline	[no description available]	medium	6	benzylisoquinoline alkaloid; isoquinoline alkaloid; isoquinolines	agrochemical; central nervous system stimulant; GABA-gated chloride channel antagonist; GABAA receptor antagonist; neurotoxin
hexylcaine	[no description available]	medium	1	benzoate ester
piperocaine	[no description available]	medium	1	benzoate ester
diperodon	[no description available]	medium	2	carbamate ester
cyclomethycaine	[no description available]	medium	1	benzoate ester
carcainium chloride	[no description available]	medium	1
azacyclonol	[no description available]	medium	1	diarylmethane
butoxamine	[no description available]	medium	1
dexpropranolol	[no description available]	medium	1	propranolol
iprindole	[no description available]	medium	1	indoles
carticaine	[no description available]	medium	1	thiophenecarboxylic acid
timolol	[no description available]	medium	1	timolol	anti-arrhythmia drug; antiglaucoma drug; antihypertensive agent; beta-adrenergic antagonist
butaclamol	[no description available]	medium	1	organic heteropentacyclic compound
etidocaine	[no description available]	medium	1	amino acid amide	local anaesthetic
diltiazem	[no description available]	medium	1	5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate	antihypertensive agent; calcium channel blocker; vasodilator agent
Arbaclofen	[no description available]	medium	1	organonitrogen compound; organooxygen compound
colforsin	[no description available]	medium	1	acetate ester; cyclic ketone; labdane diterpenoid; organic heterotricyclic compound; tertiary alpha-hydroxy ketone; triol	adenylate cyclase agonist; anti-HIV agent; antihypertensive agent; plant metabolite; platelet aggregation inhibitor; protein kinase A agonist
opromazine	[no description available]	medium	1	phenothiazines
corynanthine	[no description available]	medium	1	yohimban alkaloid
phenylisopropyladenosine	[no description available]	medium	1	aromatic amine; benzenes; hydrocarbyladenosine; purine nucleoside; secondary amino compound	adenosine A1 receptor agonist; neuroprotective agent
w 7	[no description available]	medium	1
2-n-butyl-3-(dimethylamino)-5,6-methylenedioxyindene	[no description available]	medium	1
rac 109	[no description available]	medium	1
atropine	[no description available]	medium	1
strychnine	[no description available]	medium	1	monoterpenoid indole alkaloid; organic heteroheptacyclic compound	avicide; cholinergic antagonist; glycine receptor antagonist; neurotransmitter agent; rodenticide
quinidine	[no description available]	medium	1	cinchona alkaloid	alpha-adrenergic antagonist; anti-arrhythmia drug; antimalarial; drug allergen; EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor; EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor; muscarinic antagonist; P450 inhibitor; potassium channel blocker; sodium channel blocker
cocaine	[no description available]	medium	1	benzoate ester; methyl ester; tertiary amino compound; tropane alkaloid	adrenergic uptake inhibitor; central nervous system stimulant; dopamine uptake inhibitor; environmental contaminant; local anaesthetic; mouse metabolite; plant metabolite; serotonin uptake inhibitor; sodium channel blocker; sympathomimetic agent; vasoconstrictor agent; xenobiotic
diethylstilbestrol	[no description available]	medium	1	olefinic compound; polyphenol	antifungal agent; antineoplastic agent; autophagy inducer; calcium channel blocker; carcinogenic agent; EC 1.1.1.146 (11beta-hydroxysteroid dehydrogenase) inhibitor; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor; endocrine disruptor; xenoestrogen
rauwolscine	[no description available]	medium	1	methyl 17-hydroxy-20xi-yohimban-16-carboxylate
chlorprothixene	[no description available]	medium	1	chlorprothixene
flunarizine	[no description available]	medium	1	diarylmethane
thiothixene	[no description available]	medium	1	N-methylpiperazine	anticoronaviral agent
cinnarizine	[no description available]	medium	1	diarylmethane; N-alkylpiperazine; olefinic compound	anti-allergic agent; antiemetic; calcium channel blocker; geroprotector; H1-receptor antagonist; histamine antagonist; muscarinic antagonist
quinine	[no description available]	medium	1	cinchona alkaloid	antimalarial; muscle relaxant; non-narcotic analgesic
codeine	[no description available]	medium	1	morphinane alkaloid; organic heteropentacyclic compound	antitussive; drug allergen; environmental contaminant; opioid analgesic; opioid receptor agonist; prodrug; xenobiotic
morphine	[no description available]	medium	1	morphinane alkaloid; organic heteropentacyclic compound; tertiary amino compound	anaesthetic; drug allergen; environmental contaminant; geroprotector; mu-opioid receptor agonist; opioid analgesic; plant metabolite; vasodilator agent; xenobiotic
levorphanol	[no description available]	medium	1	morphinane alkaloid
dextrorphan	[no description available]	medium	1	morphinane alkaloid
zimeldine	[no description available]	medium	1	styrenes
1-methyl-d-lysergic acid butanolamide	[no description available]	medium	1	ergot alkaloid; monocarboxylic acid amide	serotonergic antagonist; sympatholytic agent; vasoconstrictor agent
scopolamine hydrobromide	[no description available]	medium	1
my 5445	[no description available]	medium	1	pyridazines; ring assembly
cilostamide	[no description available]	medium	2	quinolines
cilostazol	[no description available]	medium	2	lactam; tetrazoles	anticoagulant; bronchodilator agent; EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor; fibrin modulating drug; neuroprotective agent; platelet aggregation inhibitor; vasodilator agent
amrinone	[no description available]	medium	1	bipyridines	EC 3.1.4.* (phosphoric diester hydrolase) inhibitor
sulmazole	[no description available]	medium	1	imidazopyridine; sulfoxide	adenosine A1 receptor antagonist; cardiotonic drug; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor
eg 626	[no description available]	medium	1	phthalazines
enoximone	[no description available]	medium	1	aromatic ketone
piroximone	[no description available]	medium	1
imazodan	[no description available]	medium	1
bufrolin	[no description available]	medium	1
y 590	[no description available]	medium	1
4,5-dihydro-6-(4-(imidazol-1-yl)phenyl)-5-methyl-3(2h)-pyridazinone	[no description available]	medium	1
zaprinast	[no description available]	medium	1	triazolopyrimidines
cuminaldehyde	[no description available]	medium	1	benzaldehydes	insecticide; plant metabolite; volatile oil component
vanillin	[no description available]	medium	1	benzaldehydes; monomethoxybenzene; phenols	anti-inflammatory agent; anticonvulsant; antioxidant; flavouring agent; plant metabolite
aniracetam	[no description available]	medium	1	N-acylpyrrolidine; pyrrolidin-2-ones
antipyrine	[no description available]	medium	1	pyrazolone	antipyretic; cyclooxygenase 3 inhibitor; environmental contaminant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
bendiocarb	[no description available]	medium	1	benzodioxoles; carbamate ester	agrochemical; carbamate insecticide; EC 3.1.1.7 (acetylcholinesterase) inhibitor
carbofuran	[no description available]	medium	1	1-benzofurans; carbamate ester	acaricide; agrochemical; avicide; carbamate insecticide; EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; nematicide
carisoprodol	[no description available]	medium	1	carbamate ester	muscle relaxant
chlorpropham	[no description available]	medium	1	benzenes; carbamate ester; monochlorobenzenes	herbicide; plant growth retardant
chlorzoxazone	[no description available]	medium	1	1,3-benzoxazoles; heteroaryl hydroxy compound; organochlorine compound	muscle relaxant; sedative
cinoxacin	[no description available]	medium	1	cinnolines; oxacycle; oxo carboxylic acid	antibacterial drug; antiinfective agent
clonidine	[no description available]	medium	1	clonidine; imidazoline
fenbendazole	[no description available]	medium	1	aryl sulfide; benzimidazoles; carbamate ester	antinematodal drug
fenofibrate	[no description available]	medium	1	aromatic ether; chlorobenzophenone; isopropyl ester; monochlorobenzenes	antilipemic drug; environmental contaminant; geroprotector; xenobiotic
fenspiride	[no description available]	medium	1	azaspiro compound
glafenine	[no description available]	medium	1	aminoquinoline; carboxylic ester; glycol; organochlorine compound; secondary amino compound	inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
glipizide	[no description available]	medium	1	aromatic amide; monocarboxylic acid amide; N-sulfonylurea; pyrazines	EC 2.7.1.33 (pantothenate kinase) inhibitor; hypoglycemic agent; insulin secretagogue
ibudilast	[no description available]	medium	2	pyrazolopyridine
idebenone	[no description available]	medium	1	1,4-benzoquinones; primary alcohol	antioxidant; ferroptosis inhibitor
beta-lapachone	[no description available]	medium	1	benzochromenone; orthoquinones	anti-inflammatory agent; antineoplastic agent; plant metabolite
leflunomide	[no description available]	medium	1	(trifluoromethyl)benzenes; isoxazoles; monocarboxylic acid amide	antineoplastic agent; antiparasitic agent; EC 1.3.98.1 [dihydroorotate oxidase (fumarate)] inhibitor; EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; hepatotoxic agent; immunosuppressive agent; non-steroidal anti-inflammatory drug; prodrug; pyrimidine synthesis inhibitor; tyrosine kinase inhibitor
meprobamate	[no description available]	medium	1	organic molecular entity
modafinil	[no description available]	medium	1	monocarboxylic acid amide; sulfoxide
oxibendazole	[no description available]	medium	1	benzimidazoles; carbamate ester
phenprobamate	[no description available]	medium	1	benzenes
propentofylline	[no description available]	medium	1	oxopurine
propoxur	[no description available]	medium	1	aromatic ether; carbamate ester	acaricide; agrochemical; carbamate insecticide; EC 3.1.1.7 (acetylcholinesterase) inhibitor
sb 206553	[no description available]	medium	1	pyrroloindole
streptonigrin	[no description available]	medium	1	pyridines; quinolone	antimicrobial agent; antineoplastic agent
thalidomide	[no description available]	medium	1	phthalimides; piperidones
tizanidine	[no description available]	medium	1	benzothiadiazole; imidazoles	alpha-adrenergic agonist; muscle relaxant
todralazine	[no description available]	medium	1	phthalazines
tolperisone	[no description available]	medium	1	aromatic ketone
delavirdine	[no description available]	medium	1	aminopyridine; indolecarboxamide; N-acylpiperazine; sulfonamide	antiviral drug; HIV-1 reverse transcriptase inhibitor
zonisamide	[no description available]	medium	1	1,2-benzoxazoles; sulfonamide	anticonvulsant; antioxidant; central nervous system drug; protective agent; T-type calcium channel blocker
zopiclone	[no description available]	medium	2	monochloropyridine; pyrrolopyrazine	central nervous system depressant; sedative
(4-(m-chlorophenylcarbamoyloxy)-2-butynyl)trimethylammonium chloride	[no description available]	medium	1
physostigmine	[no description available]	medium	3	carbamate ester; indole alkaloid	antidote to curare poisoning; EC 3.1.1.8 (cholinesterase) inhibitor; miotic
salicylaldehyde	[no description available]	medium	1	hydroxybenzaldehyde	nematicide; plant metabolite
2,4-dihydroxybenzaldehyde	[no description available]	medium	1	dihydroxybenzaldehyde
triclocarban	[no description available]	medium	1	dichlorobenzene; monochlorobenzenes; phenylureas	antimicrobial agent; antiseptic drug; disinfectant; environmental contaminant; xenobiotic
heptanal	[no description available]	medium	1	medium-chain fatty aldehyde; n-alkanal; saturated fatty aldehyde	biomarker
neostigmine bromide	[no description available]	medium	1	bromide salt
nicarbazin	[no description available]	medium	1	organic molecular entity
metaxalone	[no description available]	medium	1	aromatic ether
aminocarb	[no description available]	medium	1	carbamate ester; toluenes	acaricide; agrochemical; carbamate insecticide; EC 3.1.1.7 (acetylcholinesterase) inhibitor; molluscicide
methiocarb	[no description available]	medium	1	aryl sulfide; carbamate ester; methyl sulfide	acaricide; agrochemical; avicide; EC 3.1.1.7 (acetylcholinesterase) inhibitor; environmental contaminant; insecticide; molluscicide; xenobiotic
perillaldehyde	[no description available]	medium	1	aldehyde; olefinic compound	human metabolite; mouse metabolite; volatile oil component
promecarb	[no description available]	medium	1	alkylbenzene
propham	[no description available]	medium	1	benzenes; carbamate ester	herbicide; plant growth retardant
phenmedipham	[no description available]	medium	1	carbamate ester	environmental contaminant; herbicide; xenobiotic
metergoline	[no description available]	medium	1	carbamate ester; ergoline alkaloid	dopamine agonist; geroprotector; serotonergic antagonist
benomyl	[no description available]	medium	1	aromatic amide; benzimidazole fungicide; benzimidazoles; benzimidazolylcarbamate fungicide; carbamate ester	acaricide; anthelminthic drug; antifungal agrochemical; microtubule-destabilising agent; tubulin modulator
oxadiazon	[no description available]	medium	1	aromatic ether
toloxatone	[no description available]	medium	1	oxazolidinone; primary alcohol; toluenes
vinclozolin	[no description available]	medium	1	dicarboximide; dichlorobenzene; olefinic compound; oxazolidinone
thidiazuron	[no description available]	medium	1	ureas
oxfendazole	[no description available]	medium	1	benzimidazoles; carbamate ester; sulfoxide	antinematodal drug
talniflumate	[no description available]	medium	1	benzofurans
fenoxycarb	[no description available]	medium	1	aromatic ether; carbamate ester	environmental contaminant; insecticide; juvenile hormone mimic; xenobiotic
flupirtine	[no description available]	medium	1	aminopyridine
remoxipride	[no description available]	medium	1	dimethoxybenzene
clomazone	[no description available]	medium	1	isoxazolidinone; monochlorobenzenes	agrochemical; carotenoid biosynthesis inhibitor; environmental contaminant; herbicide; xenobiotic
sertindole	[no description available]	medium	1	heteroarylpiperidine; imidazolidinone; organochlorine compound; organofluorine compound; phenylindole	alpha-adrenergic antagonist; H1-receptor antagonist; second generation antipsychotic; serotonergic antagonist
ziprasidone	[no description available]	medium	1	1,2-benzisothiazole; indolones; organochlorine compound; piperazines	antipsychotic agent; dopaminergic antagonist; histamine antagonist; muscarinic antagonist; psychotropic drug; serotonergic antagonist
zolmitriptan	[no description available]	medium	1	oxazolidinone; tryptamines	anti-inflammatory drug; serotonergic agonist; vasoconstrictor agent
capecitabine	[no description available]	medium	1	carbamate ester; cytidines; organofluorine compound	antimetabolite; antineoplastic agent; prodrug
befuraline	[no description available]	medium	1
nefiracetam	[no description available]	medium	1	organonitrogen compound; organooxygen compound
amperozide	[no description available]	medium	1	diarylmethane; monofluorobenzenes; N-alkylpiperazine; secondary carboxamide; ureas	anxiolytic drug; dopamine uptake inhibitor; geroprotector; second generation antipsychotic; serotonergic antagonist
citronellal, (r)-isomer	[no description available]	medium	1	citronellal
phenserine	[no description available]	medium	1
linezolid	[no description available]	medium	1	acetamides; morpholines; organofluorine compound; oxazolidinone	antibacterial drug; protein synthesis inhibitor
citral	[no description available]	medium	1	enal; monoterpenoid; polyprenal	plant metabolite; volatile oil component
2-amino-3-(4-chlorobenzoyl)-5,6,7,8-tetrahydrobenzothiophene	[no description available]	medium	1
thiophanate	[no description available]	medium	1	benzimidazole precursor fungicide; carbamate ester; carbamate fungicide; thioureas	antifungal agrochemical
sb 242084	[no description available]	medium	1
chrysin	[no description available]	medium	1	7-hydroxyflavonol; dihydroxyflavone	anti-inflammatory agent; antineoplastic agent; antioxidant; EC 2.7.11.18 (myosin-light-chain kinase) inhibitor; hepatoprotective agent; plant metabolite
2-nonenal, (trans)-isomer	[no description available]	medium	1	enal; medium-chain fatty aldehyde; monounsaturated fatty aldehyde	plant metabolite
dantrolene	[no description available]	medium	1
psn 632408	[no description available]	medium	1
febantel	[no description available]	medium	1	aryl sulfide
fenobam	[no description available]	medium	1	ureas
tadalafil	[no description available]	medium	1	benzodioxoles; pyrazinopyridoindole	EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor; vasodilator agent
vinpocetine	[no description available]	medium	1	alkaloid	geroprotector
roflumilast	[no description available]	medium	2	aromatic ether; benzamides; chloropyridine; cyclopropanes; organofluorine compound	anti-asthmatic drug; phosphodiesterase IV inhibitor
d159687	[no description available]	medium	1
sildenafil	[no description available]	medium	1	piperazines; pyrazolopyrimidine; sulfonamide	EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor; vasodilator agent
zardaverine	[no description available]	medium	1	organofluorine compound; pyridazinone	anti-asthmatic drug; bronchodilator agent; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; peripheral nervous system drug
cilomilast	[no description available]	medium	1	methoxybenzenes
rp 73401	[no description available]	medium	1	aromatic ether; benzamides; chloropyridine; monocarboxylic acid amide	anti-asthmatic drug; anti-inflammatory agent; bronchodilator agent; phosphodiesterase IV inhibitor
mesembrenone	[no description available]	medium	1	pyrrolidines
tetomilast	[no description available]	medium	1
gsk 256066	[no description available]	medium	1
rpl 554	[no description available]	medium	1
apremilast	[no description available]	medium	1	aromatic ether; N-acetylarylamine; phthalimides; sulfone	non-steroidal anti-inflammatory drug; phosphodiesterase IV inhibitor
an2728	[no description available]	medium	1	aromatic ether; benzoxaborole; nitrile	antipsoriatic; non-steroidal anti-inflammatory drug; phosphodiesterase IV inhibitor
chf6001	[no description available]	medium	1
cuprizone	[no description available]	medium	2	organonitrogen compound; organooxygen compound
lysophosphatidylcholines	[no description available]	medium	1	1-O-acyl-sn-glycero-3-phosphocholine
oxidopamine	[no description available]	medium	1	benzenetriol; catecholamine; primary amino compound	drug metabolite; human metabolite; neurotoxin
sildenafil citrate	[no description available]	medium	1	citrate salt	EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor; vasodilator agent
cyclic gmp	[no description available]	medium	4	3',5'-cyclic purine nucleotide; guanyl ribonucleotide	Escherichia coli metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite
corticosterone	[no description available]	medium	1	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone	human metabolite; mouse metabolite
fluoxetine	[no description available]	medium	1	(trifluoromethyl)benzenes; aromatic ether; secondary amino compound
amyloid beta-peptides	[no description available]	medium	1
beta-carboline-3-carboxylic acid methyl ester	[no description available]	medium	1	beta-carbolines
picrotoxin	[no description available]	medium	6
picrotoxinin	[no description available]	medium	2
flunitrazepam	[no description available]	medium	12	1,4-benzodiazepinone; C-nitro compound; monofluorobenzenes	anxiolytic drug; GABAA receptor agonist; sedative
gamma-aminobutyric acid	[no description available]	medium	16	amino acid zwitterion; gamma-amino acid; monocarboxylic acid	human metabolite; neurotransmitter; Saccharomyces cerevisiae metabolite; signalling molecule
muscimol	[no description available]	medium	13	alkaloid; isoxazoles; primary amino compound	fungal metabolite; GABA agonist; oneirogen; psychotropic drug
chlorine	[no description available]	medium	6	halide anion; monoatomic chlorine	cofactor; Escherichia coli metabolite; human metabolite
tert-butylbicyclophosphorothionate	[no description available]	medium	4	organic thiophosphate
cartazolate	[no description available]	medium	6
bucladesine	[no description available]	medium	4	3',5'-cyclic purine nucleotide
azathioprine	[no description available]	medium	1	aryl sulfide; C-nitro compound; imidazoles; thiopurine	antimetabolite; antineoplastic agent; carcinogenic agent; DNA synthesis inhibitor; hepatotoxic agent; immunosuppressive agent; prodrug
4-isopropylbicyclophosphate	[no description available]	medium	2
gaboxadol	[no description available]	medium	1	oxazole
isoxazoles	[no description available]	medium	1	isoxazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
avermectin b(1)a	[no description available]	medium	3	avermectin
dextrothyroxine	[no description available]	medium	3
cl 218872	[no description available]	medium	2	pyridazines; ring assembly
niacinamide	[no description available]	medium	1	pyridine alkaloid; pyridinecarboxamide; vitamin B3	anti-inflammatory agent; antioxidant; cofactor; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor; EC 3.5.1.98 (histone deacetylase) inhibitor; Escherichia coli metabolite; geroprotector; human urinary metabolite; metabolite; mouse metabolite; neuroprotective agent; Saccharomyces cerevisiae metabolite; Sir2 inhibitor
pipequaline	[no description available]	medium	1
2-phenylpyrazolo(4,3-c)quinolin-3(5h)-one	[no description available]	medium	1
adenosine	[no description available]	medium	3	adenosines; purines D-ribonucleoside	analgesic; anti-arrhythmia drug; fundamental metabolite; human metabolite; vasodilator agent
n(6)-(2-(4-chlorophenyl)bicyclo(2.2.2.)-octyl)(3)-adenosine	[no description available]	medium	1
2-(4-chlorophenyl)-2,5-dihydropyrazolo(4,3-c)quinoline-3(3h)-one	[no description available]	medium	1
methyl 6,7-dimethoxy-4-ethyl-beta-carboline-3-carboxylate	[no description available]	medium	1	beta-carbolines
oxazoles	[no description available]	medium	2	1,3-oxazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
folic acid	[no description available]	medium	1	folic acids; N-acyl-amino acid	human metabolite; mouse metabolite; nutrient
egtazic acid	[no description available]	medium	1	diether; tertiary amino compound; tetracarboxylic acid	chelator
hypoxanthine	[no description available]	medium	1	nucleobase analogue; oxopurine; purine nucleobase	fundamental metabolite
10,10-difluoro-13-dehydroprostacyclin	[no description available]	medium	1
arachidonic acid	[no description available]	medium	1	icosa-5,8,11,14-tetraenoic acid; long-chain fatty acid; omega-6 fatty acid	Daphnia galeata metabolite; EC 3.1.1.1 (carboxylesterase) inhibitor; human metabolite; mouse metabolite
dihydropicrotoxinin	[no description available]	medium	1
adenine	[no description available]	medium	3	6-aminopurines; purine nucleobase	Daphnia magna metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
tetrodotoxin	[no description available]	medium	1	azatetracycloalkane; oxatetracycloalkane; quinazoline alkaloid	animal metabolite; bacterial metabolite; marine metabolite; neurotoxin; voltage-gated sodium channel blocker
tacrine	[no description available]	medium	1	acridines; aromatic amine	EC 3.1.1.7 (acetylcholinesterase) inhibitor
ouabain	[no description available]	medium	1	11alpha-hydroxy steroid; 14beta-hydroxy steroid; 5beta-hydroxy steroid; alpha-L-rhamnoside; cardenolide glycoside; steroid hormone	anti-arrhythmia drug; cardiotonic drug; EC 2.3.3.1 [citrate (Si)-synthase] inhibitor; EC 3.1.3.41 (4-nitrophenylphosphatase) inhibitor; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor; EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor; ion transport inhibitor; plant metabolite
carbostyril	[no description available]	medium	1	monohydroxyquinoline; quinolone	bacterial xenobiotic metabolite
aminophylline	[no description available]	medium	1	mixture	bronchodilator agent; cardiotonic drug
pyrazines	[no description available]	medium	1	diazine; pyrazines	Daphnia magna metabolite
triazoles	[no description available]	medium	1	1,2,3-triazole
guanosine triphosphate	[no description available]	medium	1	guanosine 5'-phosphate; purine ribonucleoside 5'-triphosphate	Escherichia coli metabolite; mouse metabolite; uncoupling protein inhibitor
quinazolines	[no description available]	medium	1	azaarene; mancude organic heterobicyclic parent; ortho-fused heteroarene; quinazolines
erythritol	[no description available]	medium	1	butane-1,2,3,4-tetrol	antioxidant; human metabolite; plant metabolite
glucagon	[no description available]	medium	1	peptide hormone
bufexamac	[no description available]	medium	1	aromatic ether; hydroxamic acid	antipyretic; non-narcotic analgesic; non-steroidal anti-inflammatory drug
concanavalin a	[no description available]	medium	1
pituitrin	[no description available]	medium	1
propranolol	[no description available]	medium	1	naphthalenes; propanolamine; secondary amine	anti-arrhythmia drug; antihypertensive agent; anxiolytic drug; beta-adrenergic antagonist; environmental contaminant; human blood serum metabolite; vasodilator agent; xenobiotic
glycogen	[no description available]	medium	1
etomidate	[no description available]	medium	3	ethyl ester; imidazoles	intravenous anaesthetic; sedative
zk 93423	[no description available]	medium	1	beta-carbolines
pentylenetetrazole	[no description available]	medium	1	organic heterobicyclic compound; organonitrogen heterocyclic compound
isoguvacine	[no description available]	medium	1	tetrahydropyridine
bicuculline methochloride	[no description available]	medium	1
iodinated glycerol	[no description available]	medium	1	dioxolane
1-((3,5-dichloro)-2,6-dihydroxy-4-methoxyphenyl)-1-hexanone	[no description available]	medium	1	dichlorobenzene; differentiation-inducing factor; monomethoxybenzene; resorcinols	eukaryotic metabolite; signalling molecule
dihydrolipoic acid	[no description available]	low	0	thio-fatty acid	antioxidant; human metabolite; neuroprotective agent
creatine	[no description available]	low	0	glycine derivative; guanidines; zwitterion	geroprotector; human metabolite; mouse metabolite; neuroprotective agent; nutraceutical
5,5-dimethyl-1-pyrroline-1-oxide	[no description available]	low	0	1-pyrroline nitrones	neuroprotective agent; spin trapping reagent
ethylisopropylamiloride	[no description available]	low	0	aromatic amine; guanidines; monocarboxylic acid amide; organochlorine compound; pyrazines; tertiary amino compound	anti-arrhythmia drug; neuroprotective agent; sodium channel blocker
5-methoxytryptamine	[no description available]	low	0	aromatic ether; primary amino compound; tryptamines	5-hydroxytryptamine 2A receptor agonist; 5-hydroxytryptamine 2B receptor agonist; 5-hydroxytryptamine 2C receptor agonist; antioxidant; cardioprotective agent; human metabolite; mouse metabolite; neuroprotective agent; radiation protective agent; serotonergic agonist
7-chlorokynurenic acid	[no description available]	low	0	organochlorine compound; quinolinemonocarboxylic acid	neuroprotective agent; NMDA receptor antagonist
dantrolene	[no description available]	medium	0	hydrazone; imidazolidine-2,4-dione	muscle relaxant; neuroprotective agent; ryanodine receptor antagonist
valproic acid	[no description available]	low	0	branched-chain fatty acid; branched-chain saturated fatty acid	anticonvulsant; antimanic drug; EC 3.5.1.98 (histone deacetylase) inhibitor; GABA agent; neuroprotective agent; psychotropic drug; teratogenic agent
ebselen	[no description available]	low	0	benzoselenazole	anti-inflammatory drug; antibacterial agent; anticoronaviral agent; antifungal agent; antineoplastic agent; antioxidant; apoptosis inducer; EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; EC 1.3.1.8 [acyl-CoA dehydrogenase (NADP(+))] inhibitor; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; EC 2.5.1.7 (UDP-N-acetylglucosamine 1-carboxyvinyltransferase) inhibitor; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; EC 3.1.3.25 (inositol-phosphate phosphatase) inhibitor; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; EC 3.5.4.1 (cytosine deaminase) inhibitor; EC 5.1.3.2 (UDP-glucose 4-epimerase) inhibitor; enzyme mimic; ferroptosis inhibitor; genotoxin; hepatoprotective agent; neuroprotective agent; radical scavenger
ethoxyquin	[no description available]	low	0	aromatic ether; quinolines	antifungal agrochemical; food antioxidant; genotoxin; geroprotector; herbicide; Hsp90 inhibitor; neuroprotective agent; UDP-glucuronosyltransferase activator
felbamate	[no description available]	low	0	carbamate ester	anticonvulsant; neuroprotective agent
fasudil	[no description available]	low	0	isoquinolines; N-sulfonyldiazepane	antihypertensive agent; calcium channel blocker; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; geroprotector; neuroprotective agent; nootropic agent; vasodilator agent
kynurenic acid	[no description available]	low	0	monohydroxyquinoline; quinolinemonocarboxylic acid	G-protein-coupled receptor agonist; human metabolite; neuroprotective agent; nicotinic antagonist; NMDA receptor antagonist; Saccharomyces cerevisiae metabolite
memantine	[no description available]	low	0	adamantanes; primary aliphatic amine	antidepressant; antiparkinson drug; dopaminergic agent; neuroprotective agent; NMDA receptor antagonist
palmidrol	[no description available]	low	0	endocannabinoid; N-(long-chain-acyl)ethanolamine; N-(saturated fatty acyl)ethanolamine	anti-inflammatory drug; anticonvulsant; antihypertensive agent; neuroprotective agent
pj-34	[no description available]	low	0	phenanthridines; secondary carboxamide; tertiary amino compound	angiogenesis inhibitor; anti-inflammatory agent; antiatherosclerotic agent; antineoplastic agent; apoptosis inducer; cardioprotective agent; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor; neuroprotective agent
4-phenylbutyric acid, sodium salt	[no description available]	low	0	organic sodium salt	EC 3.5.1.98 (histone deacetylase) inhibitor; geroprotector; neuroprotective agent; orphan drug; prodrug
methylene blue	[no description available]	low	0	organic chloride salt	acid-base indicator; antidepressant; antimalarial; antimicrobial agent; antioxidant; cardioprotective agent; EC 1.4.3.4 (monoamine oxidase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; EC 4.6.1.2 (guanylate cyclase) inhibitor; fluorochrome; histological dye; neuroprotective agent; physical tracer
cycloheximide	[no description available]	low	0	antibiotic fungicide; cyclic ketone; dicarboximide; piperidine antibiotic; piperidones; secondary alcohol	anticoronaviral agent; bacterial metabolite; ferroptosis inhibitor; neuroprotective agent; protein synthesis inhibitor
methylprednisolone	[no description available]	low	0	6-methylprednisolone; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	adrenergic agent; anti-inflammatory drug; antiemetic; environmental contaminant; neuroprotective agent; xenobiotic
methylparaben	[no description available]	low	0	paraben	antifungal agent; antimicrobial food preservative; neuroprotective agent; plant metabolite
cytidine diphosphate choline	[no description available]	low	0	nucleotide-(amino alcohol)s; phosphocholines	human metabolite; mouse metabolite; neuroprotective agent; psychotropic drug; Saccharomyces cerevisiae metabolite
tetramethylpyrazine	[no description available]	low	0	alkaloid; pyrazines	antineoplastic agent; apoptosis inhibitor; bacterial metabolite; neuroprotective agent; platelet aggregation inhibitor; vasodilator agent
pn 401	[no description available]	low	0	acetate ester; uridines	neuroprotective agent; orphan drug; prodrug
argon	[no description available]	low	0	monoatomic argon; noble gas atom; p-block element atom	food packaging gas; neuroprotective agent
6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid	[no description available]	low	0	chromanol; monocarboxylic acid; phenols	antioxidant; ferroptosis inhibitor; neuroprotective agent; radical scavenger; Wnt signalling inhibitor
tenocyclidine	[no description available]	low	0	piperidines; tertiary amino compound; thiophenes	central nervous system stimulant; hallucinogen; neuroprotective agent; NMDA receptor antagonist
baicalin	[no description available]	low	0	dihydroxyflavone; glucosiduronic acid; glycosyloxyflavone; monosaccharide derivative	antiatherosclerotic agent; antibacterial agent; anticoronaviral agent; antineoplastic agent; antioxidant; cardioprotective agent; EC 2.7.7.48 (RNA-directed RNA polymerase) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; ferroptosis inhibitor; neuroprotective agent; non-steroidal anti-inflammatory drug; plant metabolite; prodrug
epigallocatechin gallate	[no description available]	low	0	flavans; gallate ester; polyphenol	antineoplastic agent; antioxidant; apoptosis inducer; geroprotector; Hsp90 inhibitor; neuroprotective agent; plant metabolite
norvaline	[no description available]	low	0	2-aminopentanoic acid; L-alpha-amino acid zwitterion	bacterial metabolite; hypoglycemic agent; neuroprotective agent
pyrrolidine dithiocarbamate	[no description available]	low	0	dithiocarbamic acids; pyrrolidines	anticonvulsant; antineoplastic agent; geroprotector; neuroprotective agent; NF-kappaB inhibitor; radical scavenger
pinocembrin	[no description available]	low	0	(2S)-flavan-4-one; dihydroxyflavanone	antineoplastic agent; antioxidant; metabolite; neuroprotective agent; vasodilator agent
sesamin	[no description available]	low	0	benzodioxoles; furofuran; lignan	antineoplastic agent; neuroprotective agent; plant metabolite
fangchinoline	[no description available]	low	0	aromatic ether; bisbenzylisoquinoline alkaloid; macrocycle	anti-HIV-1 agent; anti-inflammatory agent; antineoplastic agent; antioxidant; neuroprotective agent; plant metabolite
rivastigmine	[no description available]	low	0	carbamate ester; tertiary amino compound	cholinergic drug; EC 3.1.1.8 (cholinesterase) inhibitor; neuroprotective agent
loganin	[no description available]	low	0	beta-D-glucoside; cyclopentapyran; enoate ester; iridoid monoterpenoid; methyl ester; monosaccharide derivative; secondary alcohol	anti-inflammatory agent; EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.2.1.20 (alpha-glucosidase) inhibitor; EC 3.4.23.46 (memapsin 2) inhibitor; neuroprotective agent; plant metabolite
7-ketocholesterol	[no description available]	low	0	3beta-hydroxy-Delta(5)-steroid; 3beta-sterol; 7-oxo steroid; cholestanoid	neuroprotective agent
delta(9)-tetrahydrocannabinolic acid	[no description available]	low	0	benzochromene; diterpenoid; hydroxy monocarboxylic acid; phytocannabinoid; polyketide	anti-inflammatory agent; biomarker; metabolite; neuroprotective agent
galgravin	[no description available]	low	0	aryltetrahydrofuran; dimethoxybenzene; lignan; ring assembly	bone density conservation agent; neuroprotective agent; plant metabolite; platelet aggregation inhibitor
s-methylthiocitrulline	[no description available]	low	0	imidothiocarbamic ester; L-arginine derivative; L-ornithine derivative; non-proteinogenic L-alpha-amino acid	EC 1.14.13.39 (nitric oxide synthase) inhibitor; neuroprotective agent
ta 0910	[no description available]	low	0	oligopeptide	analgesic; neuroprotective agent; nootropic agent
cgp 42112a	[no description available]	low	0	benzyl ester; oligopeptide; pyridinecarboxamide	angiotensin receptor agonist; anti-inflammatory agent; antineoplastic agent; neuroprotective agent; vasodilator agent
3-(2,2,2-trimethylhydrazine)propionate	[no description available]	low	0	ammonium betaine	cardioprotective agent; EC 1.14.11.1 (gamma-butyrobetaine dioxygenase) inhibitor; neuroprotective agent
27-hydroxycholesterol	[no description available]	low	0	26-hydroxycholesterol	apoptosis inducer; human metabolite; mouse metabolite; neuroprotective agent
rubimaillin	[no description available]	low	0	benzochromene; methyl ester; phenols	acyl-CoA:cholesterol acyltransferase 2 inhibitor; anti-inflammatory agent; antineoplastic agent; apoptosis inducer; neuroprotective agent; NF-kappaB inhibitor; plant metabolite
cyanidin	[no description available]	low	0	5-hydroxyanthocyanidin	antioxidant; metabolite; neuroprotective agent
ilomastat	[no description available]	low	0	hydroxamic acid; L-tryptophan derivative; N-acyl-amino acid	anti-inflammatory agent; antibacterial agent; antineoplastic agent; EC 3.4.24.24 (gelatinase A) inhibitor; neuroprotective agent
lanthionine ketimine	[no description available]	low	0	1,4-thiazine; dicarboxylic acid; sulfur-containing amino acid	anti-inflammatory agent; human urinary metabolite; neuroprotective agent
tempol	[no description available]	low	0	aminoxyls; hydroxypiperidine	anti-inflammatory agent; antineoplastic agent; apoptosis inducer; catalyst; hepatoprotective agent; nephroprotective agent; neuroprotective agent; radical scavenger
schizandrin b	[no description available]	low	0	aromatic ether; cyclic acetal; organic heterotetracyclic compound; oxacycle; tannin	anti-asthmatic agent; anti-inflammatory agent; antilipemic drug; antioxidant; apoptosis inhibitor; hepatoprotective agent; nephroprotective agent; neuroprotective agent; plant metabolite
salvigenin	[no description available]	low	0	monohydroxyflavone; trimethoxyflavone	antilipemic drug; antineoplastic agent; apoptosis inhibitor; autophagy inducer; hypoglycemic agent; immunomodulator; neuroprotective agent; plant metabolite
fasudil hydrochloride	[no description available]	low	0	hydrochloride	antihypertensive agent; calcium channel blocker; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; neuroprotective agent; nootropic agent; vasodilator agent
6-methylthiohexyl isothiocyanate	[no description available]	low	0	isothiocyanate; methyl sulfide	antineoplastic agent; Arabidopsis thaliana metabolite; EC 4.1.1.17 (ornithine decarboxylase) inhibitor; neuroprotective agent
anacardic acid	[no description available]	low	0	hydroxy monocarboxylic acid; hydroxybenzoic acid	anti-inflammatory agent; antibacterial agent; anticoronaviral agent; apoptosis inducer; EC 2.3.1.48 (histone acetyltransferase) inhibitor; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; neuroprotective agent; plant metabolite
sb 203580	[no description available]	low	0	imidazoles; monofluorobenzenes; pyridines; sulfoxide	EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; geroprotector; Hsp90 inhibitor; neuroprotective agent
dizocilpine	[no description available]	low	0	secondary amino compound; tetracyclic antidepressant	anaesthetic; anticonvulsant; neuroprotective agent; nicotinic antagonist; NMDA receptor antagonist
memantine hydrochloride	[no description available]	low	0	hydrochloride	antidepressant; antiparkinson drug; dopaminergic agent; neuroprotective agent; NMDA receptor antagonist
methyl 3,4-dihydroxybenzoate	[no description available]	low	0	catechols; methyl ester	antioxidant; neuroprotective agent; plant metabolite
carnosine	[no description available]	low	0	amino acid zwitterion; dipeptide	anticonvulsant; antineoplastic agent; antioxidant; Daphnia magna metabolite; geroprotector; human metabolite; mouse metabolite; neuroprotective agent
theanine	[no description available]	low	0	amino acid zwitterion; N(5)-alkyl-L-glutamine	geroprotector; neuroprotective agent; plant metabolite
neriifolin	[no description available]	low	0	cardenolide glycoside	cardiotonic drug; neuroprotective agent; toxin
ginsenoside re	[no description available]	low	0	12beta-hydroxy steroid; 3beta-hydroxy-4,4-dimethylsteroid; 3beta-hydroxy steroid; beta-D-glucoside; disaccharide derivative; ginsenoside; tetracyclic triterpenoid	anti-inflammatory agent; antineoplastic agent; antioxidant; nephroprotective agent; neuroprotective agent; plant metabolite
ginsenoside rg1	[no description available]	low	0	12beta-hydroxy steroid; 3beta-hydroxy-4,4-dimethylsteroid; beta-D-glucoside; ginsenoside; tetracyclic triterpenoid	neuroprotective agent; pro-angiogenic agent
notoginsenoside r1	[no description available]	low	0	12beta-hydroxy steroid; 3beta-hydroxy-4,4-dimethylsteroid; 3beta-hydroxy steroid; beta-D-glucoside; disaccharide derivative; ginsenoside; tetracyclic triterpenoid	antioxidant; apoptosis inducer; neuroprotective agent; phytoestrogen; plant metabolite
5,11-diethyl-5,6,11,12-tetrahydrochrysene-2,8-diol	[no description available]	low	0	carbotetracyclic compound; polyphenol	estrogen receptor agonist; estrogen receptor antagonist; geroprotector; neuroprotective agent
dimethyloxalylglycine	[no description available]	low	0	glycine derivative; methyl ester; secondary carboxamide	EC 1.14.11.29 (hypoxia-inducible factor-proline dioxygenase) inhibitor; neuroprotective agent
rhapontin	[no description available]	low	0	rhaponticin	angiogenesis inhibitor; anti-allergic agent; anti-inflammatory agent; antilipemic drug; antineoplastic agent; apoptosis inducer; EC 2.3.1.85 (fatty acid synthase) inhibitor; hypoglycemic agent; neuroprotective agent; plant metabolite
glycerylphosphorylcholine	[no description available]	low	0	phosphocholines; sn-glycerol 3-phosphates	Escherichia coli metabolite; human metabolite; mouse metabolite; neuroprotective agent; parasympatholytic; Saccharomyces cerevisiae metabolite
huperzine a	[no description available]	low	0	organic heterotricyclic compound; primary amino compound; pyridone; sesquiterpene alkaloid	EC 3.1.1.7 (acetylcholinesterase) inhibitor; neuroprotective agent; nootropic agent; plant metabolite
curcumin	[no description available]	low	0	aromatic ether; beta-diketone; diarylheptanoid; enone; polyphenol	anti-inflammatory agent; antifungal agent; antineoplastic agent; biological pigment; contraceptive drug; dye; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; EC 1.1.1.21 (aldehyde reductase) inhibitor; EC 1.1.1.25 (shikimate dehydrogenase) inhibitor; EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor; EC 1.8.1.9 (thioredoxin reductase) inhibitor; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; EC 3.5.1.98 (histone deacetylase) inhibitor; flavouring agent; food colouring; geroprotector; hepatoprotective agent; immunomodulator; iron chelator; ligand; lipoxygenase inhibitor; metabolite; neuroprotective agent; nutraceutical; radical scavenger
aurapten	[no description available]	low	0	coumarins; monoterpenoid	antihypertensive agent; antineoplastic agent; antioxidant; apoptosis inducer; dopaminergic agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; gamma-secretase modulator; gastrointestinal drug; hepatoprotective agent; matrix metalloproteinase inhibitor; neuroprotective agent; plant metabolite; PPARalpha agonist; vulnerary
n-(4-(n-(3-methoxypyrazin-2-yl)sulfamoyl)phenyl)-3-(5-nitrothiophene-2-yl)acrylamide	[no description available]	low	0	pyrazines; sulfonamide; thiophenes	necroptosis inhibitor; neuroprotective agent
amn082	[no description available]	low	0	benzenes; diamine; diarylmethane; secondary amino compound	metabotropic glutamate receptor agonist; neuroprotective agent
rasagiline	[no description available]	low	0	indanes; secondary amine; terminal acetylenic compound	EC 1.4.3.4 (monoamine oxidase) inhibitor; neuroprotective agent
ferrostatin-1	[no description available]	medium	0	ethyl ester; primary arylamine; substituted aniline	antifungal agent; antioxidant; ferroptosis inhibitor; neuroprotective agent; radiation protective agent; radical scavenger
4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione	[no description available]	low	0	benzenes; thiadiazolidine	anti-inflammatory agent; antineoplastic agent; apoptosis inducer; EC 2.7.11.26 (tau-protein kinase) inhibitor; neuroprotective agent
sb 415286	[no description available]	low	0	C-nitro compound; maleimides; monochlorobenzenes; phenols; secondary amino compound; substituted aniline	antioxidant; apoptosis inducer; EC 2.7.11.26 (tau-protein kinase) inhibitor; neuroprotective agent
gossypin	[no description available]	low	0	7-hydroxyflavonol; glycosyloxyflavone; monosaccharide derivative; pentahydroxyflavone	neuroprotective agent; plant metabolite
hinokiflavone	[no description available]	low	0	aromatic ether; biflavonoid; hydroxyflavone	antineoplastic agent; metabolite; neuroprotective agent
morin	[no description available]	low	0	7-hydroxyflavonol; pentahydroxyflavone	angiogenesis modulating agent; anti-inflammatory agent; antibacterial agent; antihypertensive agent; antineoplastic agent; antioxidant; EC 5.99.1.2 (DNA topoisomerase) inhibitor; hepatoprotective agent; metabolite; neuroprotective agent
pterostilbene	[no description available]	low	0	diether; methoxybenzenes; stilbenol	anti-inflammatory agent; antineoplastic agent; antioxidant; apoptosis inducer; hypoglycemic agent; neuroprotective agent; neurotransmitter; plant metabolite; radical scavenger
caffeic acid phenethyl ester	[no description available]	low	0	alkyl caffeate ester	anti-inflammatory agent; antibacterial agent; antineoplastic agent; antioxidant; antiviral agent; immunomodulator; metabolite; neuroprotective agent
acteoside	[no description available]	low	0	catechols; cinnamate ester; disaccharide derivative; glycoside; polyphenol	anti-inflammatory agent; antibacterial agent; antileishmanial agent; neuroprotective agent; plant metabolite
tocotrienol, alpha	[no description available]	low	0	tocotrienol; vitamin E	ferroptosis inhibitor; human metabolite; neuroprotective agent; plant metabolite
menatetrenone	[no description available]	low	0	menaquinone	anti-inflammatory agent; antioxidant; bone density conservation agent; human metabolite; neuroprotective agent
arachidonyl-2-chloroethylamide	[no description available]	low	0	fatty amide; organochlorine compound; secondary carboxamide; synthetic cannabinoid	CB1 receptor agonist; CB2 receptor agonist; neuroprotective agent
(3r)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone	[no description available]	low	0	morpholines; naphthyl ketone; organic heterotricyclic compound; synthetic cannabinoid	analgesic; apoptosis inhibitor; neuroprotective agent
cannabigerol	[no description available]	low	0	phytocannabinoid; resorcinols	anti-inflammatory agent; antibacterial agent; antioxidant; appetite enhancer; cannabinoid receptor agonist; neuroprotective agent; plant metabolite
su 11248	[no description available]	low	0	monocarboxylic acid amide; pyrroles	angiogenesis inhibitor; antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; immunomodulator; neuroprotective agent; vascular endothelial growth factor receptor antagonist
tetrahydroxycurcumin	[no description available]	low	0	beta-diketone; catechols; diarylheptanoid; enone; polyphenol	anti-inflammatory agent; neuroprotective agent; plant metabolite
dizocilpine maleate	[no description available]	low	0	maleate salt; tetracyclic antidepressant	anaesthetic; anticonvulsant; neuroprotective agent; nicotinic antagonist; NMDA receptor antagonist
sdz eaa 494	[no description available]	low	0	monocarboxylic acid; olefinic compound; phosphonic acids; piperazinecarboxylic acid; tertiary amino compound	anticonvulsant; neuroprotective agent; NMDA receptor antagonist
germacrone	[no description available]	low	0	germacrane sesquiterpenoid; olefinic compound	androgen antagonist; anti-inflammatory agent; antifeedant; antifungal agent; antimicrobial agent; antineoplastic agent; antioxidant; antitussive; antiviral agent; apoptosis inducer; autophagy inducer; hepatoprotective agent; insecticide; neuroprotective agent; plant metabolite; volatile oil component
salvianolic acid B	[no description available]	low	0	1-benzofurans; catechols; dicarboxylic acid; enoate ester; polyphenol	anti-inflammatory agent; antidepressant; antineoplastic agent; antioxidant; apoptosis inducer; autophagy inhibitor; cardioprotective agent; hepatoprotective agent; hypoglycemic agent; neuroprotective agent; osteogenesis regulator; plant metabolite
ro 25-6981	[no description available]	low	0	benzenes; phenols; piperidines; secondary alcohol; tertiary amino compound	anticonvulsant; antidepressant; neuroprotective agent; NMDA receptor antagonist
bis(7)-tacrine	[no description available]	low	0	secondary amino compound	apoptosis inhibitor; EC 1.14.13.39 (nitric oxide synthase) inhibitor; EC 3.1.1.7 (acetylcholinesterase) inhibitor; neuroprotective agent
jasplakinolide	[no description available]	low	0	cyclodepsipeptide; phenols	actin polymerisation inducer; animal metabolite; antifungal agent; antineoplastic agent; apoptosis inducer; marine metabolite; neuroprotective agent
ursodoxicoltaurine	[no description available]	low	0	bile acid taurine conjugate	anti-inflammatory agent; apoptosis inhibitor; bone density conservation agent; cardioprotective agent; human metabolite; neuroprotective agent
l 779976	[no description available]	low	0	benzimidazoles; indoles; piperidinecarboxamide; primary amino compound; secondary carboxamide	neuroprotective agent; somatostatin receptor agonist
ginsenoside rb1	[no description available]	low	0	ginsenoside; glycoside; tetracyclic triterpenoid	anti-inflammatory drug; anti-obesity agent; apoptosis inhibitor; neuroprotective agent; plant metabolite; radical scavenger
NNC 55-0396 (free base)	[no description available]	low	0	benzimidazoles; cyclopropanecarboxylate ester; organofluorine compound; tertiary amino compound; tetralins	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; neuroprotective agent; potassium channel blocker; T-type calcium channel blocker
ly 379268	[no description available]	low	0	amino dicarboxylic acid; bridged compound; organic heterobicyclic compound	antipsychotic agent; anxiolytic drug; metabotropic glutamate receptor agonist; neuroprotective agent
glu-asp-arg	[no description available]	low	0	tripeptide	neuroprotective agent
n-arachidonoyl l-serine	[no description available]	low	0	N-(fatty acyl)-L-alpha-amino acid	cannabinoid receptor agonist; mammalian metabolite; neuroprotective agent; pro-angiogenic agent; vasodilator agent
n-benzylhexadecanamide	[no description available]	low	0	macamide; secondary carboxamide	EC 3.5.1.99 (fatty acid amide hydrolase) inhibitor; neuroprotective agent; plant metabolite
np 031112	[no description available]	low	0	benzenes; naphthalenes; thiadiazolidine	anti-inflammatory agent; apoptosis inducer; EC 2.7.11.26 (tau-protein kinase) inhibitor; neuroprotective agent
ginsenoside rd	[no description available]	low	0	beta-D-glucoside; ginsenoside; tetracyclic triterpenoid	anti-inflammatory drug; apoptosis inducer; immunosuppressive agent; neuroprotective agent; plant metabolite; vulnerary
n,n'-dibenzhydrylethane-1,2-diamine dihydrochloride	[no description available]	low	0	hydrochloride	geroprotector; metabotropic glutamate receptor agonist; neuroprotective agent
glycoursodeoxycholic acid	[no description available]	low	0	bile acid glycine conjugate; N-acylglycine	human blood serum metabolite; neuroprotective agent
ginsenoside rb3	[no description available]	low	0	12beta-hydroxy steroid; beta-D-glucoside; disaccharide derivative; ginsenoside; tetracyclic triterpenoid	antidepressant; antioxidant; cardioprotective agent; neuroprotective agent; NMDA receptor antagonist; plant metabolite
astragaloside IV	[no description available]	low	0	pentacyclic triterpenoid; triterpenoid saponin	anti-inflammatory agent; antioxidant; EC 4.2.1.1 (carbonic anhydrase) inhibitor; neuroprotective agent; plant metabolite; pro-angiogenic agent
protectin d1	[no description available]	low	0	dihydroxydocosahexaenoic acid; protectin; secondary allylic alcohol	anti-inflammatory agent; apoptosis inhibitor; hepatoprotective agent; human xenobiotic metabolite; neuroprotective agent; PPARgamma agonist; specialised pro-resolving mediator
forapin	[no description available]	low	0	peptidyl amide; polypeptide	animal metabolite; antineoplastic agent; apoptosis inducer; EC 2.7.11.13 (protein kinase C) inhibitor; hepatoprotective agent; neuroprotective agent; venom
astressin	[no description available]	low	0	homodetic cyclic peptide; polypeptide	corticotropin-releasing factor receptor antagonist; neuroprotective agent
liraglutide	[no description available]	low	0	lipopeptide; polypeptide	glucagon-like peptide-1 receptor agonist; neuroprotective agent
nnc 55-0396	[no description available]	low	0	hydrochloride	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; neuroprotective agent; potassium channel blocker; T-type calcium channel blocker
albiflorin	[no description available]	low	0	benzoate ester; beta-D-glucoside; bridged compound; gamma-lactone; monoterpene glycoside; secondary alcohol	neuroprotective agent; plant metabolite
SL-327	[no description available]	low	0	(trifluoromethyl)benzenes; enamine; nitrile; organic sulfide; primary amino compound; substituted aniline	EC 2.7.12.2 (mitogen-activated protein kinase kinase) inhibitor; neuroprotective agent
apelin-13 peptide	[no description available]	low	0	oligopeptide	antihypertensive agent; autophagy inhibitor; biomarker; human metabolite; neuroprotective agent
p-Glu-Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Met-Pro-Phe	[no description available]	low	0	polypeptide	apoptosis inhibitor; human metabolite; neuroprotective agent
oleuropein aglycone	[no description available]	low	0	catechols; diester; lactol; methyl ester; pyrans; secoiridoid	anti-inflammatory agent; antioxidant; mTOR inhibitor; neuroprotective agent; plant metabolite; TRPA1 channel agonist
semaglutide	[no description available]	low	0	lipopeptide; polypeptide	anti-obesity agent; appetite depressant; glucagon-like peptide-1 receptor agonist; hypoglycemic agent; neuroprotective agent
maysin	[no description available]	low	0	disaccharide derivative; flavone C-glycoside; secondary alpha-hydroxy ketone; tetrahydroxyflavone	insecticide; neuroprotective agent; plant metabolite
((5z)5-(1,3-benzodioxol-5-yl)methylene-2-phenylamino-3,5-dihydro-4h-imidazol-4-one)	[no description available]	low	0	benzodioxoles; imidazolone; substituted aniline	autophagy inducer; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor; EC 2.7.12.1 (dual-specificity kinase) inhibitor; neuroprotective agent; nootropic agent
rifampin	[no description available]	medium	0	cyclic ketal; hydrazone; N-iminopiperazine; N-methylpiperazine; rifamycins; semisynthetic derivative; zwitterion	angiogenesis inhibitor; antiamoebic agent; antineoplastic agent; antitubercular agent; DNA synthesis inhibitor; EC 2.7.7.6 (RNA polymerase) inhibitor; Escherichia coli metabolite; geroprotector; leprostatic drug; neuroprotective agent; pregnane X receptor agonist; protein synthesis inhibitor
apelin-12 peptide	[no description available]	low	0	oligopeptide	biomarker; human blood serum metabolite; human metabolite; neuroprotective agent
benzquinamide	[no description available]	low	0	monocarboxylic acid amide	antiemetic; antipsychotic agent; H1-receptor antagonist; muscarinic antagonist; sedative
chlormezanone	[no description available]	low	0	1,3-thiazine; lactam; monochlorobenzenes; sulfone	antipsychotic agent; anxiolytic drug; muscle relaxant
loxapine	[no description available]	low	0	dibenzooxazepine	antipsychotic agent; dopaminergic antagonist
methiothepin	[no description available]	low	0	aryl sulfide; dibenzothiepine; N-alkylpiperazine; tertiary amino compound	antipsychotic agent; dopaminergic antagonist; geroprotector; serotonergic antagonist
ritanserin	[no description available]	low	0	organofluorine compound; piperidines; thiazolopyrimidine	antidepressant; antipsychotic agent; anxiolytic drug; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; serotonergic antagonist
sulpiride	[no description available]	low	0	benzamides; N-alkylpyrrolidine; sulfonamide	antidepressant; antiemetic; antipsychotic agent; dopaminergic antagonist
azaperone	[no description available]	low	0	aminopyridine; aromatic ketone; monofluorobenzenes; N-alkylpiperazine; N-arylpiperazine; tertiary amino compound	antipsychotic agent; dopaminergic antagonist
levosulpiride	[no description available]	low	0	sulpiride	antidepressant; antiemetic; antipsychotic agent; dopaminergic antagonist
dapiprazole	[no description available]	low	0	N-alkylpiperazine; N-arylpiperazine; pyridines	alpha-adrenergic antagonist; antipsychotic agent; miotic; ophthalmology drug
ly 404039	[no description available]	low	0	bridged compound; dicarboxylic acid; non-proteinogenic amino acid derivative; organic heterobicyclic compound; sulfone	antipsychotic agent; anxiolytic drug; dopamine agonist; metabotropic glutamate receptor agonist
n,n-dipropyl-2-(4-methoxy-3-(2-phenylethoxy)phenyl)ethylamine monohydrochloride	[no description available]	low	0	aromatic ether; hydrochloride; methoxybenzenes; tertiary amino compound	antipsychotic agent; receptor modulator
pimavanserin	[no description available]	low	0	aromatic ether; monofluorobenzenes; piperidines; tertiary amino compound; ureas	5-hydroxytryptamine 2A receptor inverse agonist; antipsychotic agent; serotonergic antagonist
alprazolam	[no description available]	low	0	organochlorine compound; triazolobenzodiazepine	anticonvulsant; anxiolytic drug; GABA agonist; muscle relaxant; sedative; xenobiotic
clobazam	[no description available]	low	0	1,4-benzodiazepinone; organochlorine compound	anticonvulsant; anxiolytic drug; GABA modulator
clonazepam	[no description available]	low	0	1,4-benzodiazepinone; monochlorobenzenes	anticonvulsant; anxiolytic drug; GABA modulator
chlorazepate	[no description available]	low	0	1,4-benzodiazepinone	anticonvulsant; anxiolytic drug; GABA modulator; prodrug
nordazepam	[no description available]	low	0	1,4-benzodiazepinone; organochlorine compound	anticonvulsant; anxiolytic drug; GABA modulator; human metabolite; sedative
estazolam	[no description available]	low	0	triazoles; triazolobenzodiazepine	anticonvulsant; anxiolytic drug; GABA modulator
fludiazepam	[no description available]	low	0	1,4-benzodiazepinone; organochlorine compound; organofluorine compound	anxiolytic drug
flurazepam	[no description available]	low	0	1,4-benzodiazepinone; monofluorobenzenes; organochlorine compound; tertiary amino compound	anticonvulsant; anxiolytic drug; GABAA receptor agonist; sedative
midazolam	[no description available]	low	0	imidazobenzodiazepine; monofluorobenzenes; organochlorine compound	anticonvulsant; antineoplastic agent; anxiolytic drug; apoptosis inducer; central nervous system depressant; GABAA receptor agonist; general anaesthetic; muscle relaxant; sedative
mirtazapine	[no description available]	low	0	benzazepine; tetracyclic antidepressant	alpha-adrenergic antagonist; anxiolytic drug; H1-receptor antagonist; histamine antagonist; oneirogen; serotonergic antagonist
oxazepam	[no description available]	low	0	1,4-benzodiazepinone; organochlorine compound	anxiolytic drug; environmental contaminant; xenobiotic
zaleplon	[no description available]	low	0	nitrile; pyrazolopyrimidine	anticonvulsant; anxiolytic drug; central nervous system depressant; sedative
didesethylflurazepam	[no description available]	low	0	1,4-benzodiazepinone; monofluorobenzenes; organochlorine compound; primary amino compound	anticonvulsant; anxiolytic drug; drug metabolite; GABAA receptor agonist; sedative
buspirone hydrochloride	[no description available]	low	0	hydrochloride	anxiolytic drug; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; sedative; serotonergic agonist
adinazolam	[no description available]	low	0	triazolobenzodiazepine	anticonvulsant; antidepressant; anxiolytic drug; sedative
midazolam hydrochloride	[no description available]	low	0	hydrochloride; imidazobenzodiazepine	anticonvulsant; antineoplastic agent; anxiolytic drug; apoptosis inducer; central nervous system depressant; GABAA receptor agonist; general anaesthetic; muscle relaxant; sedative
paroxetine	[no description available]	low	0	aromatic ether; benzodioxoles; organofluorine compound; piperidines	antidepressant; anxiolytic drug; hepatotoxic agent; P450 inhibitor; serotonin uptake inhibitor
paroxetine hydrochloride	[no description available]	low	0	hydrochloride	antidepressant; anxiolytic drug; hepatotoxic agent; P450 inhibitor; serotonin uptake inhibitor
glutaurine	[no description available]	low	0	dipeptide zwitterion; dipeptide; L-glutamine derivative; sulfonic acid	anticonvulsant; anxiolytic drug; hormone; human metabolite; mammalian metabolite; mouse metabolite
amperozide hydrochloride	[no description available]	low	0	hydrochloride	anxiolytic drug; dopamine uptake inhibitor; geroprotector; second generation antipsychotic; serotonergic antagonist
nicotine	[no description available]	low	0	3-(1-methylpyrrolidin-2-yl)pyridine	anxiolytic drug; biomarker; immunomodulator; mitogen; neurotoxin; nicotinic acetylcholine receptor agonist; peripheral nervous system drug; phytogenic insecticide; plant metabolite; psychotropic drug; teratogenic agent; xenobiotic
tandospirone	[no description available]	low	0	bridged compound; dicarboximide; N-alkylpiperazine; N-arylpiperazine; pyrimidines	antidepressant; anxiolytic drug
1-((4-fluorobenzoylamino)ethyl)-4-(7-methoxy-1-naphthyl)piperazine hydrochloride	[no description available]	low	0	hydrochloride	anxiolytic drug; serotonergic agonist
spinosin	[no description available]	low	0	dihydroxyflavone; flavone C-glycoside; monomethoxyflavone	anxiolytic drug; plant metabolite
clorazepate dipotassium	[no description available]	low	0	potassium salt	anticonvulsant; anxiolytic drug; GABA modulator; prodrug
ANA-12	[no description available]	low	0	1-benzothiophenes; caprolactams; secondary carboxamide	antidepressant; anxiolytic drug; tropomyosin-related kinase B receptor antagonist
6-methyl-2-(phenylethynyl)pyridine	[no description available]	low	0	acetylenic compound; methylpyridines	anxiolytic drug; metabotropic glutamate receptor antagonist
clavulanic acid	[no description available]	low	0	oxapenam	antibacterial drug; anxiolytic drug; bacterial metabolite; EC 3.5.2.6 (beta-lactamase) inhibitor
fluvoxamine	[no description available]	low	0	(trifluoromethyl)benzenes; 5-methoxyvalerophenone O-(2-aminoethyl)oxime	antidepressant; anxiolytic drug; serotonin uptake inhibitor
paroxetine maleate	[no description available]	low	0	maleate salt	antidepressant; anxiolytic drug; hepatotoxic agent; P450 inhibitor; serotonin uptake inhibitor
2-methyl-6-(phenylethynyl)pyridine hydrochloride	[no description available]	low	0	hydrochloride	anxiolytic drug; metabotropic glutamate receptor antagonist
vortioxetine	[no description available]	low	0	aryl sulfide; N-arylpiperazine	antidepressant; anxiolytic drug; serotonergic agonist; serotonergic antagonist
demethylmirtazapine	[no description available]	low	0	benzazepine; tetracyclic antidepressant	alpha-adrenergic antagonist; anxiolytic drug; H1-receptor antagonist; histamine antagonist; human xenobiotic metabolite; serotonergic antagonist
bupropion	[no description available]	low	0	aromatic ketone; monochlorobenzenes; secondary amino compound	antidepressant; environmental contaminant; xenobiotic
7,8-dihydroxyflavone	[no description available]	low	0	dihydroxyflavone	antidepressant; antineoplastic agent; antioxidant; plant metabolite; tropomyosin-related kinase B receptor agonist
n-acetylphenylalanine	[no description available]	low	0	N-acetyl-amino acid; phenylalanine derivative	antidepressant; metabolite
am 251	[no description available]	low	0	amidopiperidine; carbohydrazide; dichlorobenzene; organoiodine compound; pyrazoles	antidepressant; antineoplastic agent; apoptosis inducer; CB1 receptor antagonist
amoxapine	[no description available]	low	0	dibenzooxazepine	adrenergic uptake inhibitor; antidepressant; dopaminergic antagonist; geroprotector; serotonin uptake inhibitor
cyclobenzaprine	[no description available]	low	0	carbotricyclic compound	antidepressant; muscle relaxant; tranquilizing drug
lamotrigine	[no description available]	low	0	1,2,4-triazines; dichlorobenzene; primary arylamine	anticonvulsant; antidepressant; antimanic drug; calcium channel blocker; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; environmental contaminant; excitatory amino acid antagonist; geroprotector; non-narcotic analgesic; xenobiotic
lofepramine	[no description available]	low	0	aromatic ketone; dibenzoazepine; monochlorobenzenes; tertiary amino compound	antidepressant
minaprine	[no description available]	low	0	morpholines; pyridazines; secondary amine	antidepressant; antiparkinson drug; cholinergic drug; dopamine uptake inhibitor; serotonin uptake inhibitor
moclobemide	[no description available]	low	0	benzamides; monochlorobenzenes; morpholines	antidepressant; environmental contaminant; xenobiotic
clorgyline	[no description available]	low	0	aromatic ether; dichlorobenzene; terminal acetylenic compound; tertiary amino compound	antidepressant; EC 1.4.3.4 (monoamine oxidase) inhibitor
nefazodone	[no description available]	low	0	aromatic ether; monochlorobenzenes; N-alkylpiperazine; N-arylpiperazine; triazoles	alpha-adrenergic antagonist; analgesic; antidepressant; serotonergic antagonist; serotonin uptake inhibitor
nisoxetine	[no description available]	low	0	aromatic ether; secondary amino compound	adrenergic uptake inhibitor; antidepressant
pioglitazone	[no description available]	low	0	aromatic ether; pyridines; thiazolidinediones	antidepressant; cardioprotective agent; EC 2.7.1.33 (pantothenate kinase) inhibitor; EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; geroprotector; hypoglycemic agent; insulin-sensitizing drug; PPARgamma agonist; xenobiotic
trimipramine	[no description available]	low	0	dibenzoazepine; tertiary amino compound	antidepressant; environmental contaminant; xenobiotic
venlafaxine	[no description available]	low	0	cyclohexanols; monomethoxybenzene; tertiary alcohol; tertiary amino compound	adrenergic uptake inhibitor; analgesic; antidepressant; dopamine uptake inhibitor; environmental contaminant; serotonin uptake inhibitor; xenobiotic
tryptophan	[no description available]	low	0	erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid zwitterion; L-alpha-amino acid; proteinogenic amino acid; tryptophan zwitterion; tryptophan	antidepressant; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite
imipramine hydrochloride	[no description available]	low	0	hydrochloride	antidepressant
thymoquinone	[no description available]	low	0	1,4-benzoquinones	adjuvant; anti-inflammatory agent; antidepressant; antineoplastic agent; antioxidant; cardioprotective agent; plant metabolite
cyclobenzaprine hydrochloride	[no description available]	low	0	hydrochloride	antidepressant; muscle relaxant
8-bromo cyclic adenosine monophosphate	[no description available]	low	0	3',5'-cyclic purine nucleotide; adenyl ribonucleotide; organobromine compound	antidepressant; protein kinase agonist
lofepramine hydrochloride	[no description available]	low	0	hydrochloride	antidepressant
amineptin	[no description available]	low	0	amino acid; carbocyclic fatty acid; carbotricyclic compound; secondary amino compound	antidepressant; dopamine uptake inhibitor
atomoxetine hydrochloride	[no description available]	low	0	hydrochloride	adrenergic uptake inhibitor; antidepressant
atomoxetine	[no description available]	low	0	aromatic ether; secondary amino compound; toluenes	adrenergic uptake inhibitor; antidepressant; environmental contaminant; xenobiotic
duloxetine hydrochloride	[no description available]	low	0	duloxetine hydrochloride	antidepressant
rubidium chloride	[no description available]	low	0	inorganic chloride; rubidium molecular entity	antidepressant; biomarker
trazodone hydrochloride	[no description available]	low	0	hydrochloride	adrenergic antagonist; antidepressant; H1-receptor antagonist; sedative; serotonin uptake inhibitor
sertraline hydrochloride	[no description available]	low	0	hydrochloride	antidepressant; serotonin uptake inhibitor
secoisolariciresinol	[no description available]	low	0	secoisolariciresinol	antidepressant; phytoestrogen; plant metabolite
lithium sulfate	[no description available]	low	0	metal sulfate	antidepressant
dexamisole	[no description available]	low	0	6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole	antidepressant
clomipramine hydrochloride	[no description available]	low	0	hydrochloride	anticoronaviral agent; antidepressant; serotonergic antagonist; serotonergic drug
sertraline	[no description available]	low	0	dichlorobenzene; secondary amino compound; tetralins	antidepressant; serotonin uptake inhibitor
brexanolone	[no description available]	low	0	3-hydroxy-5alpha-pregnan-20-one	antidepressant; GABA modulator; human metabolite; intravenous anaesthetic; sedative
desvenlafaxine	[no description available]	low	0	cyclohexanols; phenols; tertiary amino compound	antidepressant; drug metabolite; marine xenobiotic metabolite
escitalopram	[no description available]	low	0	1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile	antidepressant; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
tetrindole	[no description available]	low	0	racemate	antidepressant; EC 1.4.3.4 (monoamine oxidase) inhibitor; serotonergic agonist
eicosapentaenoic acid	[no description available]	low	0	icosapentaenoic acid; omega-3 fatty acid	anticholesteremic drug; antidepressant; antineoplastic agent; Daphnia galeata metabolite; fungal metabolite; micronutrient; mouse metabolite; nutraceutical
cotinine	[no description available]	low	0	N-alkylpyrrolidine; pyridines; pyrrolidin-2-ones; pyrrolidine alkaloid	antidepressant; biomarker; human xenobiotic metabolite; plant metabolite
fluoxetine	[no description available]	low	0	N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine	antidepressant; serotonin uptake inhibitor
(R)-fluoxetine	[no description available]	low	0	N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine	antidepressant; serotonin uptake inhibitor
ly 367265	[no description available]	low	0	dihydropyridine; fluoroindole; tertiary amino compound; thiadiazoloquinoline	antidepressant; geroprotector; serotonergic antagonist; serotonin uptake inhibitor
quercetin 3-o-glucuronide	[no description available]	low	0	beta-D-glucosiduronic acid; quercetin O-glycoside	antidepressant; antioxidant; metabolite
trimipramine maleate	[no description available]	low	0	maleate salt	antidepressant
lespenefril	[no description available]	low	0	alpha-L-rhamnoside; dihydroxyflavone; glycosyloxyflavone; monosaccharide derivative; polyphenol	anti-inflammatory agent; antidepressant; antineoplastic agent; apoptosis inducer; bone density conservation agent; hypoglycemic agent; immunomodulator; plant metabolite
clovoxamine	[no description available]	low	0	5-methoxyvalerophenone O-(2-aminoethyl)oxime; monochlorobenzenes	antidepressant
protriptyline hydrochloride	[no description available]	low	0	hydrochloride	antidepressant
flibanserin	[no description available]	low	0	benzimidazoles; N-alkylpiperazine; N-arylpiperazine; organofluorine compound	antidepressant; serotonergic agonist; serotonergic antagonist
vilazodone hydrochloride	[no description available]	low	0	hydrochloride	antidepressant; serotonergic agonist; serotonin uptake inhibitor
vilazodone	[no description available]	low	0	1-benzofurans; indoles; monocarboxylic acid amide; N-alkylpiperazine; N-arylpiperazine; nitrile	antidepressant; serotonergic agonist; serotonin uptake inhibitor
(R)-fluoxetine hydrochloride	[no description available]	low	0	hydrochloride	antidepressant; serotonin uptake inhibitor
(S)-fluoxetine hydrochloride	[no description available]	low	0	hydrochloride	antidepressant; serotonin uptake inhibitor
aprepitant	[no description available]	low	0	(trifluoromethyl)benzenes; cyclic acetal; morpholines; triazoles	antidepressant; antiemetic; neurokinin-1 receptor antagonist; peripheral nervous system drug; substance P receptor antagonist
levomefolate calcium	[no description available]	low	0	organic calcium salt	antidepressant
bryostatin 1	[no description available]	low	0	acetate ester; bryostatins; cyclic hemiketal; enoate ester; methyl ester; organic heterotetracyclic compound; secondary alcohol	alpha-secretase activator; anti-HIV-1 agent; antineoplastic agent; marine metabolite; protein kinase C agonist
ici 136,753	[no description available]	low	0	pyrazolopyridine
repsox	[no description available]	low	0	pyrazolopyridine
5-amino-1-(2-pyridinyl)-4-pyrazolecarboxylic acid ethyl ester	[no description available]	low	0	pyrazolopyridine
4,6-bis(trifluoromethyl)-1,2-dihydropyrazolo[3,4-b]pyridin-3-one	[no description available]	low	0	pyrazolopyridine
4-(4-chlorophenyl)-1-(6-fluoro-2-pyridinyl)-3-pyrazolamine	[no description available]	low	0	pyrazolopyridine
3-(4-morpholinyl)-4-(2-pyridinyl)-N-[3-(trifluoromethyl)phenyl]-1-pyrazolecarboxamide	[no description available]	low	0	pyrazolopyridine
3-methyl-1-[2-(2H-tetrazol-5-yl)ethyl]-4,6-bis(trifluoromethyl)pyrazolo[3,4-b]pyridine	[no description available]	low	0	pyrazolopyridine
1-Benzyl-3-pyridin-3-yl-1H-pyrazole-4-carbaldehyde	[no description available]	low	0	pyrazolopyridine	anticoronaviral agent
4-[(1-ethyl-6-methyl-4-pyrazolo[3,4-b]pyridinyl)oxymethyl]benzonitrile	[no description available]	low	0	pyrazolopyridine
N-[2-(1-tert-butyl-3,4,6-trimethyl-5-pyrazolo[3,4-b]pyridinyl)ethyl]carbamic acid ethyl ester	[no description available]	low	0	pyrazolopyridine
4-chloro-1-methyl-5-pyrazolo[3,4-b]pyridinecarboxylic acid ethyl ester	[no description available]	low	0	pyrazolopyridine
N-[2-(2,3,4-trimethoxyphenyl)ethyl]-2-pyrazolo[1,5-a]pyridinecarboxamide	[no description available]	low	0	pyrazolopyridine
pexacerfont	[no description available]	low	0	pyrazolopyridine
bay 41-8543	[no description available]	low	0	pyrazolopyridine
apixaban	[no description available]	low	0	aromatic ether; lactam; piperidones; pyrazolopyridine	anticoagulant; EC 3.4.21.6 (coagulation factor Xa) inhibitor
jte 013	[no description available]	low	0	chloropyridine; pyrazolopyridine	anti-asthmatic agent; anti-inflammatory agent; antineoplastic agent; osteogenesis regulator; pro-angiogenic agent; sphingosine-1-phosphate receptor 2 antagonist
bay 63-2521	[no description available]	low	0	aminopyrimidine; carbamate ester; organofluorine compound; pyrazolopyridine	antihypertensive agent; soluble guanylate cyclase activator
bay 60-4552	[no description available]	low	0	aminopyrimidine; carbamate ester; monofluorobenzenes; pyrazolopyridine	antihypertensive agent; drug metabolite; soluble guanylate cyclase activator; vasodilator agent
2-amino-8-ethyl-4-methyl-6-(1H-pyrazol-5-yl)-7-pyrido[2,3-d]pyrimidinone	[no description available]	low	0	pyrazolopyridine
vericiguat	[no description available]	low	0	aminopyrimidine; carbamate ester; organofluorine compound; pyrazolopyridine	antihypertensive agent; soluble guanylate cyclase activator; vasodilator agent
carbonyl cyanide m-chlorophenyl hydrazone	[no description available]	low	0	hydrazone; monochlorobenzenes; nitrile	antibacterial agent; geroprotector; ionophore
carbonyl cyanide p-trifluoromethoxyphenylhydrazone	[no description available]	low	0	aromatic ether; hydrazone; nitrile; organofluorine compound	ATP synthase inhibitor; geroprotector; ionophore
bisantrene	[no description available]	low	0	anthracenes; hydrazone; imidazolidines	antineoplastic agent
3,5,5-trimethyl-4H-pyrazole-1-carbothioamide	[no description available]	low	0	hydrazone
or 1259	[no description available]	low	0	hydrazone; nitrile; pyridazinone	anti-arrhythmia drug; cardiotonic drug; EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor; vasodilator agent
mitoguazone	[no description available]	low	0	guanidines; hydrazone	antineoplastic agent; apoptosis inducer; EC 4.1.1.50 (adenosylmethionine decarboxylase) inhibitor
rhosin	[no description available]	low	0	D-tryptophan derivative; hydrazone; quinoxaline derivative	antineoplastic agent; RhoA inhibitor; RhoC inhibitor
nifurtoinol	[no description available]	low	0	hydrazone; imidazolidine-2,4-dione; nitrofuran antibiotic; organonitrogen heterocyclic antibiotic	antibacterial drug; antiinfective agent; hepatotoxic agent
triacsin c	[no description available]	low	0	hydrazone; nitroso compound; olefinic compound	antimalarial; apoptosis inhibitor; bacterial metabolite; EC 3.1.1.64 (retinoid isomerohydrolase) inhibitor; EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; vasodilator agent
cyclopentylidene-[4-(4-chlorophenyl)thiazol-2-yl]hydrazone	[no description available]	low	0	1,3-thiazoles; hydrazone; monochlorobenzenes	EC 2.3.1.48 (histone acetyltransferase) inhibitor
n'-(3,4-dihydroxybenzylidene)-3-hydroxy-2-naphthahydrazide	[no description available]	low	0	catechols; hydrazide; hydrazone; naphthols	EC 3.6.5.5 (dynamin GTPase) inhibitor
amlodipine	[no description available]	low	0	dihydropyridine; ethyl ester; methyl ester; monochlorobenzenes; primary amino compound	antihypertensive agent; calcium channel blocker; vasodilator agent
clofibrate	[no description available]	low	0	aromatic ether; ethyl ester; monochlorobenzenes	anticholesteremic drug; antilipemic drug; geroprotector; PPARalpha agonist
loratadine	[no description available]	low	0	benzocycloheptapyridine; ethyl ester; N-acylpiperidine; organochlorine compound; tertiary carboxamide	anti-allergic agent; cholinergic antagonist; geroprotector; H1-receptor antagonist
malathion	[no description available]	low	0	diester; ethyl ester; organic thiophosphate
meperidine	[no description available]	low	0	ethyl ester; piperidinecarboxylate ester; tertiary amino compound	antispasmodic drug; kappa-opioid receptor agonist; mu-opioid receptor agonist; opioid analgesic
molsidomine	[no description available]	low	0	ethyl ester; morpholines; oxadiazole; zwitterion	antioxidant; apoptosis inhibitor; cardioprotective agent; nitric oxide donor; vasodilator agent
tazarotene	[no description available]	low	0	acetylenic compound; ethyl ester; pyridines; retinoid; thiochromane	keratolytic drug; prodrug; teratogenic agent
diethyl phthalate	[no description available]	low	0	diester; ethyl ester; phthalate ester	neurotoxin; plasticiser; teratogenic agent
ethyl benzoate	[no description available]	low	0	benzoate ester; ethyl ester	flavouring agent; fragrance; volatile oil component
ethyl lactate	[no description available]	low	0	ethyl ester; lactate ester; secondary alcohol	metabolite
ethyl formate	[no description available]	low	0	ethyl ester; formate ester	fumigant; plant metabolite
ethyl-p-hydroxybenzoate	[no description available]	low	0	ethyl ester; paraben	antifungal agent; antimicrobial food preservative; phytoestrogen; plant metabolite
ethyl acetate	[no description available]	low	0	acetate ester; ethyl ester; volatile organic compound	EC 3.4.19.3 (pyroglutamyl-peptidase I) inhibitor; metabolite; polar aprotic solvent; Saccharomyces cerevisiae metabolite
ethyl acetoacetate	[no description available]	low	0	ethyl ester	antibacterial agent; flavouring agent; plant metabolite
anileridine	[no description available]	low	0	ethyl ester; piperidinecarboxylate ester; substituted aniline	opioid analgesic; opioid receptor agonist
ethyl propiolate	[no description available]	low	0	ethyl ester; terminal acetylenic compound; ynoate ester
dicarbethoxydihydrocollidine	[no description available]	low	0	dihydropyridine; ethyl ester	hepatic steatosis inducing agent
ethyl mandelate	[no description available]	low	0	ethyl ester; secondary alcohol
ethyl n-alpha-acetyl-tyrosinate	[no description available]	low	0	acetamides; ethyl ester; L-tyrosine derivative; phenols
diphenoxylate	[no description available]	low	0	ethyl ester; nitrile; piperidinecarboxylate ester; tertiary amine	antidiarrhoeal drug
malaoxon	[no description available]	low	0	diester; ethyl ester; organic thiophosphate
phenthoate, (+-)-isomer	[no description available]	low	0	ethyl ester; organic thiophosphate; organothiophosphate insecticide	acaricide; agrochemical; EC 3.1.1.7 (acetylcholinesterase) inhibitor
ethyl 4-dimethylaminobenzoate	[no description available]	low	0	benzoate ester; ethyl ester; tertiary amino compound
pyrazophos	[no description available]	low	0	ethyl ester; organic thiophosphate; pyrazolopyrimidine	antifungal agrochemical; insecticide; phospholipid biosynthesis inhibitor; profungicide
dichlozolinate	[no description available]	low	0	dicarboximide; dichlorobenzene; ethyl ester; oxazolidinone
quizalofop-ethyl	[no description available]	low	0	aromatic ether; ethyl ester; organochlorine compound; quinoxaline derivative
benfuracarb	[no description available]	low	0	1-benzofurans; carbamate ester; ethyl ester	agrochemical; carbamate insecticide; EC 3.1.1.7 (acetylcholinesterase) inhibitor
quinapril	[no description available]	low	0	dicarboxylic acid monoester; ethyl ester; isoquinolines; tertiary carboxamide	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; prodrug
chlorimuron ethyl	[no description available]	low	0	aromatic ether; ethyl ester; N-sulfonylurea; organochlorine pesticide; pyrimidines; sulfamoylbenzoate	agrochemical; EC 2.2.1.6 (acetolactate synthase) inhibitor; proherbicide
cilazapril, anhydrous	[no description available]	low	0	dicarboxylic acid monoester; ethyl ester; pyridazinodiazepine	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; prodrug
3-carbethoxypsoralen	[no description available]	low	0	ethyl ester; psoralens
aloxistatin	[no description available]	low	0	epoxide; ethyl ester; L-leucine derivative; monocarboxylic acid amide	anticoronaviral agent; cathepsin B inhibitor
ethyl tyrosine ester	[no description available]	low	0	ethyl ester; L-tyrosyl ester
coumarin 314	[no description available]	low	0	7-aminocoumarins; ethyl ester	fluorochrome
monoethyl phthalate	[no description available]	low	0	ethyl ester; phthalic acid monoester	metabolite
benzoyltyrosine ethyl ester	[no description available]	low	0	benzamides; ethyl ester; L-tyrosine derivative; phenols	chromogenic compound
ethyl protocatechuate	[no description available]	low	0	catechols; ethyl ester	antibacterial agent; antioxidant; apoptosis inducer; EC 1.14.11.2 (procollagen-proline dioxygenase) inhibitor; plant metabolite
carfentrazone-ethyl	[no description available]	low	0	ethyl ester	proherbicide
ethyl-3-(n-n-butyl-n-acetyl)aminopropionate	[no description available]	low	0	acetamides; ethyl ester; tertiary carboxamide
perindopril	[no description available]	low	0	alpha-amino acid ester; dicarboxylic acid monoester; ethyl ester; organic heterobicyclic compound	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
erythromycin ethylsuccinate	[no description available]	low	0	cyclic ketone; erythromycin derivative; ethyl ester; succinate ester
ethyl cinnamate	[no description available]	low	0	alkyl cinnamate; ethyl ester
ethyl 1-[4-(4-chlorobenzenesulfonamido)phenyl]-5-(trifluoromethyl)pyrazole-4-carboxylate	[no description available]	low	0	ethyl ester; monochlorobenzenes; organofluorine compound; pyrazoles; sulfonamide
nemadipine-a	[no description available]	low	0	dicarboxylic acids and O-substituted derivatives; diester; dihydropyridine; ethyl ester; pentafluorobenzenes	calcium channel blocker
monastrol	[no description available]	low	0	enoate ester; ethyl ester; phenols; racemate; thioureas	antileishmanial agent; antimitotic; antineoplastic agent; EC 3.5.1.5 (urease) inhibitor
4-[dimethylamino(oxo)methyl]-3,5-dimethyl-1H-pyrrole-2-carboxylic acid ethyl ester	[no description available]	low	0	ethyl ester; pyrroles; tertiary carboxamide
diethyl maleate	[no description available]	low	0	ethyl ester; maleate ester	glutathione depleting agent
etretinate	[no description available]	low	0	enoate ester; ethyl ester; retinoid	keratolytic drug
spirapril	[no description available]	low	0	azaspiro compound; dicarboxylic acid monoester; dipeptide; dithioketal; ethyl ester; pyrrolidinecarboxylic acid; secondary amino compound; tertiary carboxamide	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; prodrug
ethyl caffeate	[no description available]	low	0	alkyl caffeate ester; ethyl ester; hydroxycinnamic acid	anti-inflammatory agent; antineoplastic agent; metabolite
benazepril	[no description available]	low	0	benzazepine; dicarboxylic acid monoester; ethyl ester; lactam	EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; prodrug
ramipril	[no description available]	low	0	azabicycloalkane; cyclopentapyrrole; dicarboxylic acid monoester; dipeptide; ethyl ester	bradykinin receptor B2 agonist; cardioprotective agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; matrix metalloproteinase inhibitor; prodrug
zr-512	[no description available]	low	0	ethyl ester; farnesane sesquiterpenoid	juvenile hormone mimic
imidapril	[no description available]	low	0	dicarboxylic acid monoester; dipeptide; ethyl ester; imidazolidines; N-acylurea; secondary amino compound	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; prodrug
ximelagatran	[no description available]	low	0	amidoxime; azetidines; carboxamide; ethyl ester; hydroxylamines; secondary amino compound; secondary carboxamide; tertiary carboxamide	anticoagulant; EC 3.4.21.5 (thrombin) inhibitor; prodrug; serine protease inhibitor
trandolapril	[no description available]	low	0	dicarboxylic acid monoester; dipeptide; ethyl ester; organic heterobicyclic compound; secondary amino compound; tertiary carboxamide	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; prodrug
cinidon-ethyl	[no description available]	low	0	ethyl ester; isoindoles; monochlorobenzenes	herbicide

etazolate

Description

Cross-References

Synonyms (56)

Research Excerpts

Overview

Actions

Treatment

Roles (7)

Drug Classes (3)

Protein Targets (39)

Potency Measurements

Inhibition Measurements

Biological Processes (75)

Molecular Functions (39)

Ceullar Components (20)

Bioassays (38)

Research

Studies (89)

Study Types

Clinical Trials (1)

Trial Overview

Research Highlights

Long-term Use (1)

Condition	Relationship Strength	Studies	Trials
Academic Disorder, Developmental	low	1	0
Acute Brain Injuries	low	1	0
Acute Confusional Senile Dementia	medium	3	1
Acute Post-Traumatic Stress Disorder	low	2	0
Adult Learning Disabilities	low	1	0
Adult Learning Disorders	low	1	0
Age-Related Memory Disorders	low	3	0
Aging	low	1	0
Allergic Reaction	low	1	0
Allergy	low	1	0
Alzheimer Dementia	medium	3	1
Alzheimer Disease, Early Onset	medium	3	1
Alzheimer Disease, Late Onset	medium	3	1
Alzheimer Sclerosis	medium	3	1
Alzheimer Syndrome	medium	3	1
Alzheimer Type Senile Dementia	medium	3	1
Alzheimer-Type Dementia (ATD)	medium	3	1
Alzheimer's Disease	medium	3	1
Alzheimer's Disease, Focal Onset	medium	3	1
Alzheimer's Diseases	medium	3	1
Anemia, Fanconi	low	1	0
Anxiety	low	4	0
Anxiety Disorders	low	3	0
Anxiety Neuroses	low	3	0
Anxiety States, Neurotic	low	3	0
Autosomal Dominant Juvenile Parkinson Disease	low	1	0
Autosomal Dominant Juvenile Parkinsonism	low	1	0
Autosomal Dominant Parkinsonism	low	1	0
Autosomal Recessive Juvenile Parkinson Disease	low	1	0
Autosomal Recessive Juvenile Parkinsonism	low	1	0
Autosomal Recessive Parkinsonism	low	1	0
Brain Edema	low	1	0
Brain Injuries	low	1	0
Brain Injuries, Acute	low	1	0
Brain Injuries, Focal	low	1	0
Brain Injuries, Traumatic	low	1	0
Brain Lacerations	low	1	0
Brain Swelling	low	1	0
Cerebral Edema	low	1	0
Cerebral Edema, Cytotoxic	low	1	0
Cerebral Edema, Vasogenic	low	1	0
Chromosome 6-Linked Autosomal Recessive Parkinsonism	low	1	0
Chronic Disease	low	1	0
Chronic Illness	low	1	0
Chronic Post-Traumatic Stress Disorder	low	2	0
Chronically Ill	low	1	0
Clinically Isolated CNS Demyelinating Syndrome	low	2	0
Clinically Isolated Syndrome, CNS Demyelinating	low	2	0
Cognition Disorders	low	1	0
Congenital Zika Syndrome	low	1	0
Congenital Zika Virus Infection	low	1	0
Contact Dermatitis	low	1	0
Cytotoxic Brain Edema	low	1	0
Cytotoxic Cerebral Edema	low	1	0
Delayed Onset Post-Traumatic Stress Disorder	low	2	0
Dementia, Alzheimer Type	medium	3	1
Dementia, Presenile	medium	3	1
Dementia, Primary Senile Degenerative	medium	3	1
Dementia, Senile	medium	3	1
Demyelinating Diseases	low	2	0
Demyelinating Disorders	low	2	0
Demyelination	low	2	0
Depression	low	8	0
Depression, Endogenous	low	2	0
Depression, Neurotic	low	2	0
Depression, Unipolar	low	2	0
Depressive Disorder	low	2	0
Depressive Syndrome	low	2	0
Dermatitis Venenata	low	1	0
Dermatitis, Contact	low	1	0
Developmental Academic Disability	low	1	0
Developmental Academic Disorder	low	1	0
Developmental Disabilities of Scholastic Skills	low	1	0
Developmental Disorders of Scholastic Skills	low	1	0
Disease Models, Animal	low	7	0
Disease, Pulmonary	low	1	0
Diseases, Pulmonary	low	1	0
Early Onset Alzheimer Disease	medium	3	1
Eczema, Contact	low	1	0
Electrolytes	low	1	0
Emesis	low	1	0
Encephalopathy, Traumatic	low	1	0
Experimental Parkinson Disease	low	1	0
Experimental Parkinsonism	low	1	0
Experimental Parkinsonism, MPTP-Induced	low	1	0
Familial Alzheimer Disease (FAD)	medium	3	1
Familial Juvenile Parkinsonism	low	1	0
Familial Parkinson Disease, Autosomal Recessive	low	1	0
Fanconi Anemia	low	1	0
Fanconi Hypoplastic Anemia	low	1	0
Fanconi Pancytopenia	low	1	0
Fanconi Panmyelopathy	low	1	0
Fanconi's Anemia	low	1	0
Fever, Zika	low	1	0
Focal Brain Injuries	low	1	0
Focal Onset Alzheimer's Disease	medium	3	1
Hypersensitivity	low	1	0
Hypersensitivity, Contact	low	1	0
Inflammation	low	1	0
Injuries, Acute Brain	low	1	0
Injuries, Brain	low	1	0
Injury, Brain, Traumatic	low	1	0
Innate Inflammatory Response	low	1	0
Intracranial Edema	low	1	0
Itching	low	1	0
Juvenile Parkinson Disease	low	1	0
Juvenile Parkinson Disease, Autosomal Dominant	low	1	0
Juvenile Parkinson Disease, Autosomal Recessive	low	1	0
Juvenile Parkinsonism, Autosomal Dominant	low	1	0
Juvenile Parkinsonism, Autosomal Recessive	low	1	0
Late Onset Alzheimer Disease	medium	3	1
Learning Disabilities	low	1	0
Learning Disorders	low	1	0
Learning Disorders, Adult	low	1	0
Learning Disturbance	low	1	0
Lung Diseases	low	1	0
Melancholia	low	2	0
Memory Deficits	low	3	0
Memory Disorder, Semantic	low	3	0
Memory Disorder, Spatial	low	3	0
Memory Disorders	low	3	0
Memory Disorders, Age-Related	low	3	0
Memory Loss	low	3	0
Moral Injury	low	2	0
MPTP-Induced Experimental Parkinsonism	low	1	0
Muscle Contraction	low	4	0
Muscle Relaxation	low	2	0
Neuroses, Anxiety	low	3	0
Neuroses, Post-Traumatic	low	2	0
Neuroses, Posttraumatic	low	2	0
Neurosis, Depressive	low	2	0
Overinclusion	low	1	0
Parkinson Disease 2	low	1	0
Parkinson Disease 2, Autosomal Recessive Juvenile	low	1	0
Parkinson Disease Autosomal Recessive, Early Onset	low	1	0
Parkinson Disease, Autosomal Dominant. Juvenile	low	1	0
Parkinson Disease, Experimental	low	1	0
Parkinson Disease, Familial, Autosomal Recessive	low	1	0
Parkinson Disease, Juvenile	low	1	0
Parkinson Disease, Juvenile, Autosomal Dominant	low	1	0
Parkinson Disease, Juvenile, Autosomal Recessive	low	1	0
Parkinsonian Diseases	low	1	0
Parkinsonian Disorders	low	1	0
Parkinsonian Syndrome	low	1	0
Parkinsonian Syndromes	low	1	0
Parkinsonism	low	1	0
Parkinsonism, Early Onset, with Diurnal Fluctuation	low	1	0
Parkinsonism, Early-Onset, With Diurnal Fluctuation	low	1	0
Parkinsonism, Experimental	low	1	0
Parkinsonism, Juvenile	low	1	0
Parkinsonism, Juvenile, Autosomal Dominant	low	1	0
Parkinsonism, Juvenile, Autosomal Recessive	low	1	0
Post Traumatic Stress Disorder	low	2	0
Post-Traumatic Stress Disorders	low	2	0
Posttraumatic Stress Disorders	low	2	0
Presenile Alzheimer Dementia	medium	3	1
Primary Senile Degenerative Dementia	medium	3	1
Pruritis	low	1	0
Pruritus	low	1	0
PTSD	low	2	0
Pulmonary Disease	low	1	0
Pulmonary Diseases	low	1	0
Ramsay Hunt Paralysis Syndrome	low	1	0
Retention Disorders, Cognitive	low	3	0
Scholastic Skills Development Disorders	low	1	0
Semantic Memory Disorder	low	3	0
Senile Dementia, Acute Confusional	medium	3	1
Senile Dementia, Alzheimer Type	medium	3	1
Sensitivity, Contact	low	1	0
Spatial Memory Disorder	low	3	0
Stress Disorder, Post Traumatic	low	2	0
Stress Disorders, Post-Traumatic	low	2	0
Stress Disorders, Posttraumatic	low	2	0
TBI (Traumatic Brain Injury)	low	1	0
TBIs (Traumatic Brain Injuries)	low	1	0
Trauma, Brain	low	1	0
Traumatic Brain Injury	low	1	0
Traumatic Encephalopathy	low	1	0
Unipolar Depression	low	2	0
Vasogenic Brain Edema	low	1	0
Vasogenic Cerebral Edema	low	1	0
Vomiting	low	1	0
Zika Fever	low	1	0
Zika Virus Disease	low	1	0
Zika Virus Infection	low	1	0
ZikV Infection	low	1	0

Article	Year
Etazolate, a phosphodiesterase 4 inhibitor reverses chronic unpredictable mild stress-induced depression-like behavior and brain oxidative damage. Pharmacology, biochemistry, and behavior, Volume: 105	2013
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

etazolate

Description

Cross-References

Synonyms (56)

Research Excerpts

Overview

Actions

Treatment

Roles (7)

Drug Classes (3)

Protein Targets (39)

Potency Measurements

Inhibition Measurements

Biological Processes (75)

Molecular Functions (39)

Ceullar Components (20)

Bioassays (38)

Research

Studies (89)

Study Types

Clinical Trials (1)

Trial Overview

Related Drugs (630)

Related Conditions (187)

Research Highlights

Long-term Use (1)